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Autoimmune polyendocrine syndrome type 1 (APS-1) is a rare, monogenic, 
childhood-onset disorder caused by mutations in the autoimmune regulator (AIRE) 
gene. Multi-organ autoimmune disease and chronic mucocutaneous candidiasis 
(CMC) dominate the clinical phenotype, making it an important model disease for 
autoimmunity. The objective of this thesis was to perform a detailed clinical, genetic 
and immunological characterisation of Norwegian APS-1 patients and explore the 
mechanisms behind CMC susceptibility.  
Fifty-two patients were included, revealing highly variable phenotypes. Most 
patients presented with one of the major disease components during childhood, 
hypoparathyroidism, primary adrenal insufficiency or CMC; enamel hypoplasia, 
hypoparathyroidism and CMC were the most frequent features. The prevalence of 
CMC indicates a specific immunodeficiency, which was underpinned by our finding 
of dysregulated immune responses to a Candida challenge. Specifically, monocytes 
produced significantly less interleukin-23p19 (IL), an important mediator in the 
Candida defence. Properly treatment of Candida infections is important as long-term 
inflammation in the oral cavity contributes to the development of oral malignancies, 
described here as a novel entity of APS-1.  
All Norwegian patients presented tissue-specific autoantibodies, and most had 
reactivity against IL-17, IL-22, and interferon-ω. The most common AIRE mutation 
was c.967_979del13. The splice mutation c.879+1G>A was associated with a mild 
adult-onset phenotype. Possible explanations are partial activity by AIRE lacking 
exon 7 and/or a certain amount of wild-type transcripts being produced despite 
mutation in a conserved splice donor site. Finally, the influence of environmental 
factors was explored by characterizing the oral microbiome. Indeed, APS-1 patients 
have significantly altered oral microbiota, with a general reduction in the total 
number of bacterial genera and species and altered relative abundance of major phyli 




This research has implications for the diagnosis and clinical care of patients 
with APS-1 and organ-specific autoimmune diseases and offers further insight into 
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The immune system protects the host from foreign substances and consists of two 
main systems: the innate (natural, non-specific) system and the adaptive (acquired, 
specific) system (1). Coordinated crosstalk between these systems is needed for an 
effective immune response and depends on direct cell-to-cell contact and the 
production of numerous soluble mediators. Self-tolerance is crucial for a normal 
immune system and proper immune responses. However, loss of tolerance may lead 
to aberrant immune system responses to its own tissue, which are collectively defined 
as autoimmunity and may manifest as clinical disease. In this introduction, a brief 
overview of the innate and adaptive immune systems is given, and immunological 
tolerance and autoimmunity are defined. Then follows a detailed description of 
autoimmune polyendocrine syndrome type 1 (APS-1) as a severe clinical syndrome 
and model disease for studying immunological mechanisms. 
1.1 Innate immunity  
The innate immune system is the first line of defence against foreign invaders, and it 
consists of the cellular components of epithelial barriers and different subsets of 
immune cells, including neutrophils, monocytes and macrophages, natural killer cells 
and mast cells. Innate immune cells harbour specific pattern recognition receptors 
(PRRs) that recognise structures called pathogen-associated molecular patterns and 
damage-associated molecular patterns, which indicate microbe invasion or cellular 
damage, respectively (2). These PRRs are grouped into families based on their 
structure and function, including Toll-like receptors (TLRs), C-type lectin receptors 
(CLRs), RIG-I-like receptors, and NOD-like receptors. The most extensively studied 
PRRs are TLRs (3), which include both membrane-bound receptors (e.g. TLR2, 
TLR4, TLR6) and intracellular receptors (e.g. TLR3, TLR9). Collectively, TLRs 




and viral and prokaryotic nucleic acids. Activation of TLRs leads to the production of 
pro-inflammatory cytokines and chemokines. 
CLRs are essential for the recognition of the Candida species (4) and include 
Dectin receptors, which recognise glucose polymers of the cell wall of fungi (5, 6). 
Dectin-1 receptors are mainly expressed on monocytes and macrophages and 
recognise the β-glucans of the Candida cell wall. The activated Dectin-1 receptor 
induces intracellular signalling through a pathway mediated by spleen tyrosine kinase 
(SYK), caspase activation and recruitment domain-containing protein 9 (CARD9), 
and the protein Cδ (7-11) as well as the signalling pathway mediated by serine-
threonine kinase RAF1 (12). These intracellular signalling pathways terminate in 
activation of the transcription factor nuclear factor κB, which lead to cytokine 
production and internalisation of fungi (13). Engagement of Dectin-1 can also 
amplify responses of other PRRs such as TLR2 and TLR4. Figure 1 gives a 
schematic overview of the host innate immune response against fungal infections 
exemplified by Candida albicans (C. albicans). Recent evidence indicates that the 
Dectin-1 receptor also has the potential to induce epigenetic reprogramming and a 
metabolic shift in innate immune cells (14, 15). These mechanisms create a kind of 
immunological memory in innate immune cells, which is defined as trained immunity 
(16). 
Taken together, PRRs initiate intracellular signalling pathways that terminate in 
expression of cytokines and other inflammatory mediators, which further induce 
phagocytosis of microbes, activation of the complement system and recruitment of 





Figure 1. Schematic overview of the immune response against Candida albicans. 
Candida is recognised by PPRs, including TLRs and CTLs which, upon activation, induce the 
production of cytokines through the activation of NF-κB. The NLRP3 inflammasome cleaves both IL-
1β and IL-18 before they can be secreted. IL-2 is crucial for differentiation of all effector T cells. IL-12 
and IL-18 induce the differentiation of Th1 cells whereas the differentiation of Th2 cells is promoted 
by IL-4 and IL-10. Th17 cell development depends on IL-1β, IL-6 and IL-23, and is maintained by 
DOCK8. Recruitment of neutrophils to the infected tissue is promoted by IL-17. The different 
cytokines bind to their receptors, which activate adaptor molecules including STAT1, STAT3 and 
TYK2. PTPN22 is involved in BCR and TCR signalling. APC, antigen-presenting cell; BCR, B-cell 
receptor, CARD9, caspase recruitment domain 9; CD, cluster of differentiation; CTL, C-type lectin 
receptor; DC-SIGN, dendritic cell-specific ICAM-grabbing non-integrin; DEFB1, beta-defensin 1; 
DOCK8, dedicator of cytokinesis 8; IL, interleukin; IFN, interferon; MBL, mannose binding lectin, 
MMR, macrophage mannose receptor; MYD88, myeloid differentiation factor 88; NFκB, Nuclear 
factor kappa beta; NLRP3, NACHT, LRR and PYD domain-containing protein 3; PMN, 
polymorphonuclear leukocytes; PTPN22, Protein Tyrosine Phosphatase Non-Receptor type 22; 
SYK, spleen-associated tyrosine kinase; STAT, signal transducer and activator of transcription; TCR, 





1.2 Adaptive immunity  
The adaptive immune system acts as a second line of defence and has a prolonged 
activation relative to the innate system. The adaptive immune response is mediated 
by thymus-derived T lymphocytes (T cells) and their associated T-cell receptors 
(TCRs) and bone marrow-derived B lymphocytes (B cells) receptors (BCRs). The 
recognition of antigens by TCRs and BCRs is highly specific. Importantly, the 
adaptive immune system has the capacity to develop immunological memory (18, 
19).  
1.2.1 T cells 
Precursor T cells arise in the foetal liver or adult bone marrow, seed the thymus 
where they differentiate into mature T cells, exit the organ and migrate to secondary 
lymphoid organs. However, naïve T cells circulate between lymph nodes and the 
bloodstream. T cells play a crucial role in cellular immunity and can be divided into 
two major subsets based on the expression of cluster of differentiation (CD) 8 and 
CD4, which interact with the major histocompatibility complex (MHC) class I and 
MHC class II molecules, respectively. MHC class I molecules are found on all 
nucleated cells and express peptides processed from endogenous antigens, whereas 
MHC class II molecules are found on professional antigen-presenting cells (APCs), 
such as dendritic cells (DCs), macrophages and B cells, and express peptides from the 
endocytic pathway. Antigens are presented on the MHC molecules to be recognised 
by their specific TCRs. Appropriate TCR-peptide-MHC interactions activate the 
naïve T cells through complex downstream intracellular signalling cascades (20). 
Additional co-stimulation is required for the development of full effector functions, 
which is particularly dependant on interaction between the CD28 co-receptor on the T 
cells and the CD80/CD86 receptor on APCs as well as specific cytokine stimuli (21).  
 Upon activation by APCs, the naïve T cells produce interleukin (IL)-2, which 
acts in an autocrine manner driving T cells into clonal expansion (22). CD4+ T cells 
18 
 
differentiate into one of several subsets of T helper (Th) cells (e.g. Th1, Th2, Th17 
and Th22) or regulatory T cells (Tregs). For example, the Th17 linage is 
characterised by the production of IL-17 and IL-22 and is crucial for immunity 
against fungal infections. Their differentiation depends on the cytokine-transforming 
growth factor β and the presence of IL-6, IL-21 and IL-23, together with the 
induction of the Retinoic-acid-receptor-related orphan nuclear receptor γt (23, 24). 
The naïve CD8+ T cells differentiate into cytotoxic T lymphocytes upon activation. 
These differentiation processes depend on cytokines and co-stimulatory signals from 
APCs, and effector T cells navigate to the affected area through chemokine gradients. 
Most activated T cells die in apoptosis, but a small population survive giving rise to a 
pool of long-lived memory cells. Long-lived memory cells are crucial for the 
immunological memory of the adaptive immune system. 
1.2.2 B cells 
B cells develop in the bone marrow and finally mature in the spleen before they 
circulate between the bloodstream and secondary lymphoid organs searching for their 
cognate antigen. B cells act as APCs for T cells. However, their activation depend on 
the recognition of naïve antigens by their transmembrane BCRs in the presence of 
costimulatory signals from Th cells (25). Activated B cells secrete antibodies with the 
same affinity as their BCRs with the potential of neutralizing toxins, activating the 
complement system and marking microbes to facilitate phagocytosis (26). These 
effector functions depend on the isotype of the antibodies/immunoglobulins (Ig) 
which can be divided into five major classes: IgA, which is crucial in mucosal 
immunity; IgD, which is an antigen receptor of naïve B cells; IgG, which is crucial 
for opsonisation of antigens and promoting phagocytosis, complement activation, and 
neonatal immunity; IgM, which contributes in complement activation and is an 
antigen receptor of naïve B cells; and IgE, which causes mast cell degranulation.  
During activation and differentiation, B cells have the potential to change their 




progressively dominate the response (affinity maturation). This represents a way of 
fine-tuning B cell responses. Specific stimuli, particularly CD40 ligation and 
cytokines, drive further proliferation and differentiation of activated B cells into 
plasma cells and memory B cells (25), the latter of which will rapidly expand upon a 
second challenge (26). 
1.3 Mucosal immunity  
Mucosal surfaces of the human body are in intimate and constant contact with the 
external environment, representing portals for infectious agents, allergens and 
carcinogens (27). Mucosal epithelial surfaces provide physical barriers and are 
covered by mucus and antimicrobial products, including secretory IgA, that limit 
epithelial contact and penetration of foreign substances. Epithelial cells also hold 
innate immune functions and interact with intraepithelial lymphocytes to maintain 
homeostasis. The underlying specialised connective tissue, namely mucosa-
associated lymphoid tissue, mediates immune responses against invading organisms 
and provides a continuous source of memory B and T cells. Adaptive immune 
responses to invading microbes are initiated and amplified in the distant draining 
lymph nodes, with T cells being the crucial effector cells (28, 29). Importantly, 
immunosuppressive mechanisms, particularly those regulated by Tregs, inhibit 
overreaction against innocuous luminal antigens and are collectively referred to as 
oral tolerance (30).  
Mucosal surfaces of the human body also home an ecosystem of microbes 
known as the microbiota. A substantial body of evidence suggests a potential effect of 
the microbiota on physiological processes, including metabolism and immune-system 
development and function (31). Disturbances in this ecosystem, referred to as 
dysbiosis, can contribute to several pathological processes including autoimmune 
disorders (31, 32). However, Candida species are also thought to induce innate 
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immunity through interaction with epithelial surfaces (33, 34) and lymphoid cells (35, 
36). 
1.4 Immunological tolerance and autoimmunity  
1.4.1 Central tolerance 
Immunological tolerance can be defined as a lack of response by the immune system 
to an antigen with the capacity to elicit an immune response, and the term central 
tolerance includes all mechanisms by which T and B cells learn to discriminate self 
from non-self. The thymus is divided into the cortex and medulla and is the 
anatomical site where T cells mature and central tolerance occurs. Within the cortex 
and under the control of the recombination activation gene (RAG), TCRs are 
randomly generated by the somatic, convergent recombination of the variable (V), 
diversity (D), and joining (J) gene segments. Double-positive T cells bearing both 
CD4 and CD8, whose TCRs appropriately recognise the self-peptide-self-MHC 
complexes expressed on cortical thymic epithelial cells receive critical surviving 
signals. This process of testing the TCRs specificity and avidity is known as positive 
selection (37).  
After positive selection, T cells further differentiate into CD4 or CD8 single-
positive cells according to their affinity to MHC class I and II molecules, respectively 
(38, 39). The single-positive T cells then migrate to the thymic medulla where they 
interact with medullary thymic epithelial cells (mTECs) and other bone marrow-
derived APCs. The transcription factors Fez family zinc finger protein 2 and 
autoimmune regulator (AIRE) independently regulate presentation of a wide range of 
tissue-specific self-antigens in a process called promiscuous gene expression (PGE) 
(40-42). AIRE has been extensively studied, and its role in central tolerance is 
illustrated in Figure 2. T cells expressing TCRs that react strongly to self-antigens 
presented by MHC molecules induce the deletion of thymocytes by apoptosis or 




thymocytes and differentiate into functionally competent cells within the thymus 
(44). However, low-avidity TCR interactions with self-peptide and MHC class I or II 
complexes expressed by mTECs allow survival and further differentiation of single-
positive CD4 and CD8 cells to naïve T cells, which migrate from the thymus to the 
peripheral lymphoid organs (37). This process is referred to as negative selection and 
provides a mechanism by which developing T cells are exposed to a wide array of 
self-proteins, making it possible to delete autoreactive T cells from the repertoire 
(45).  
B cells mature and go through central tolerance in the bone marrow. Immature 
B cells that recognise self-antigens with a high affinity are induced to change their 
specificity by a process called receptor editing (46). Mature self-reactive B cells that 
fail in rearranging their BCRs undergo apoptosis (47). 
 
Figure 2. The role of AIRE in central tolerance. 
AIRE orchestrates the process of PGE in mTECs where a wide range of TRAs are presented for 
developing T cells. (a) In healthy individuals, T cells presenting TCRs that interact too strongly with 
TRAs go into apoptosis. (b) Due to lack of AIRE, T cells with a high affinity to self-antigens escape 
negative selection and are released into the periphery with the potential to cause autoimmune 
disease. The figure is reproduced with permission from Creative Diagnostics, US. mTEC, medullary 
thymic epithelial cell; PGE, promiscuous gene expression; TCR, T cell receptor; TRA, tissue 
restrictive self-antigens  
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1.4.2 Peripheral tolerance 
Some self-reactive lymphocytes will complete their maturation despite the 
mechanisms of central tolerance. A peripheral line of defence against these potential 
harmful cells is therefore needed. The handling of peripheral self-reactive T cells 
involves three main mechanisms (48). First, the self-reactive T cells may become 
anergic, or functionally inactivated by a lack of proper co-stimulatory signals; 
second, APCs or DCs may induce apoptosis or differentiation into peripheral Tregs 
(also called induced Tregs or adaptive Tregs); and third, self-reactive T cells may be 
suppressed by Tregs (48).  
Self-reactive B cells that escape the mechanisms of central tolerance become 
anergic if they lack proper co-stimulatory signals from T cells (49) or are deleted in 
the spleen or lymph nodes upon interaction with CD4+ T cells (50, 51).  
1.4.3 Systemic and organ-specific autoimmunity 
Autoimmune reactions reflect an imbalance between effector and regulatory immune 
responses, with the overall underlying mechanism being defective elimination and/or 
control of self-reactive lymphocytes. Autoimmune diseases have a prevalence of 
about eight percent of the populations in Europe and the United States (52) and seem 
to increase in prevalence (53). Collectively, they cause considerable morbidity and 
mortality (54), creating a worldwide economic burden of comparable magnitude to 
that of cardiovascular diseases and cancer. Autoimmune diseases generally occur 
more frequently in women, and disease onset usually occurs during adolescence (54, 
55).  
Autoimmune disorders can be divided into two major forms based on their 
autoimmune responses: systemic autoimmunity and tissue-specific autoimmunity. In 
systemic, or disseminated autoimmunity, autoimmune responses are directed against 




as deoxyribonucleic acid (DNA), ribonucleic acid (RNA), histones, and 
topoisomerases (56). This group of disorders shows diverse phenotypic expressions, 
as described in, for example, systemic lupus erythematosus (SLE) (57), sclerosing 
skin diseases (58) and Sjögrens syndrome (59). Immune modulatory agents including 
cortisone, methotrexate and anti-Tumour necrosis factor alpha (TNF-α) are 
effectively used to inhibit disease activity. In tissue-specific autoimmunity, the 
autoimmune responses are directed against self-antigens present in one particular 
organ or tissue. A typical example is autoimmune diabetes mellitus type 1, in which 
the autoimmune reaction is directed against organ-specific self-antigens (Glutamate 
decarboxylase 65, Islet antigens-2) causing autoimmune destruction strictly limited to 
insulin producing beta cells in the pancreas (60). One particular self-antigen (21-
hydroxylase (21OH)) is dominant in Addison’s disease (61), whereas patients with 
autoimmune polyendocrine syndromes (APS) have autoimmune reactions against 
several self-antigens typically located in affected endocrine tissues (62-64). In tissue-
specific autoimmunity, the autoimmune activity is self-limiting because of the 
complete destruction of the affected tissue, and substitution therapy is often required 
to compensate for the lost tissue function.  
Autoantibodies 
Interaction between specific TCRs and BCRs and a distinct self-antigen is needed to 
induce an autoimmune response. Although T cell effector functions are directly 
responsible for tissue damage, B cell response is better suited to monitor disease. In 
addition to being markers of cell-mediated autoimmunity, autoantibodies may have a 
direct causative role in disease development. For example in Grave’s disease, the 
binding of autoantibodies to the thyroid stimulating hormone receptor (TSHR) causes 
constant receptor activation, leading to an overproduction of thyroid hormone (65). 
Characterisation of autoimmune targets is likely to both reveal underlying cellular 
mechanisms and explain the origin of the clinical disease. However, autoantibodies 
can easily be assessed in peripheral blood and play a key role in both the research and 
clinical diagnosis of autoimmune diseases (66).  
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1.4.4 Genetic risk factors for pathological autoimmunity 
Complex inheritance 
Most autoimmune diseases arise from a combination of genetic predisposition, 
environmental factors and stochastic events (67). Genome-wide association studies 
have identified numerous genetic polymorphisms involved in the development of 
human diseases and several hundred loci that are associated with autoimmunity (68-
70). Human MHC molecules, known as Human Leucocyte Antigen (HLA) molecules 
(71, 72), exhibit the strongest associations across most autoimmune diseases (73). 
The specificity of the HLA-peptide-TCR interactions is crucial for an appropriate 
adaptive immune response and for maintaining self-tolerance (73). Several 
mechanisms affecting the HLA-peptide-TCR interaction have been suggested as 
contributors to the loss of self-tolerance and the development of autoimmune 
diseases, including altered TCR docking, low-affinity-mediated thymic escape, 
molecular mimicry, hybrid peptides and differences in HLA expression and stability 
(73). Furthermore, genetic polymorphisms in genes encoding immune signalling 
molecules, including the interleukin 23 receptor (IL23R) and tyrosine kinase 2 
(TYK2), are associated with autoimmune disorders (74), for example, polymorphisms 
in the IL23R gene are observed in ankylosing spondylitis, Bechet’s disease, Crohn’s 
disease, psoriasis and ulcerative colitis (75). Moreover, genes encoding proteins with 
specific functions in immunological synapses, HLA, CD40; T cell regulation, 
Cytotoxic T-lymphocyte Associated Protein 4 (CTLA-4) and Protein Tyrosine 
Phosphatase Non-Receptor Type 22; and protein coding, Interleukin 2 Receptor 
alpha chain, Fc Receptor-Like Protein 3, Thyroglobulin, and TSHR are associated 
with autoimmune thyroid diseases (76). However, multiple polymorphisms within the 
genome of each individual patient probably contribute to disease development in 





While most human autoimmune disorders result from polymorphisms of multiple 
genes involved in immune functions, some rare diseases are caused by mutations in 
single genes. Relevant examples of monogenic human autoimmune diseases are APS-
1 caused by mutations in the AIRE gene (62, 64) and immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome caused by mutations in 
the forkhead box P3 (FOXP3) gene (77). Studies of APS-1 patients have revealed the 
essential role of AIRE in thymic negative selection and central tolerance (78, 79), and 
studies of IPEX-patients have highlighted the crucial role of FOXP3 in development 
and function of Tregs (77, 80). The CTLA-4 gene encodes a protein receptor that acts 
as an immune checkpoint, downregulating immune responses. Mutations in this gene 
are found in families with Mendelian multi-organ autoimmune disorders and are 
associated with impairment of the suppressive functions of Tregs (81, 82). Similarly, 
mutations in genes involved in Fas-mediated signalling cause autoimmune 
lymphoproliferative syndrome (ALPS), which is clinically defined by 
lymphoproliferative disease, autoimmune cytopenia and susceptibility to malignancy 
(83). Protein kinase Cδ deficiency can cause both SLE and an ALPS-like disease (84-
86), and some extremely rare monogenic autoimmune diseases of the endocrine 
system are also described (87). Monogenic diseases are powerful in vivo models for 
immunological research, and studies of these patients have already provided insight 
on several biological pathways in immune homeostasis. 
1.4.5 Environmental factors in autoimmunity  
Environmental factors contribute to the heterogeneity found in the human immune 
system (88), and several environmental factors and external triggers have been 
suggested as contributing factors in the development of autoimmune diseases. In 
celiac patients, an immune response against the gliadin fraction of the gluten protein, 
driven by enterocytes and gliadin-reactive CD4+ T cells, promotes inflammation in 
the upper small intestine (89). This interaction between gluten and immune, genetic 
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and environmental factors in celiac disease is unique because the environmental 
trigger which causes the disease is well-known (89, 90). Interestingly, elimination of 
gluten in the diet induces clinical improvement and histologic recovery in most 
patients.  
 Drugs represent another class of external triggers that may induce autoimmune 
disorders (91), the most documented of which is probably drug-induced SLE (92). 
Although the exact mechanisms involved are not well understood, continuous 
exposure to several different agents, such as thiazide diuretics, calcium channel 
blockers, terbinafine, angiotensin-converting enzyme inhibitors and immune 
modulators, has the potential to induce SLE (92). New cancer treatment involving 
blocking immune check-points (programmed cell death-1 inhibitors, CTLA-4 
antibodies) and enhancing anti-tumour immunity can also cause a wide range of 
immune-related adverse events including autoimmune disorders (93-95). 
There is also an established link between infections and autoimmune diseases 
(96-98), and many possible explanations have emerged including release of hidden 
antigens, epitope spread, molecular mimicry, the adjuvant effect and excessive PRRs 
activation. For example, systemic infections trigger relapses in patients with 
relapsing-remitting multiple sclerosis (MS) through the activation of myelin-specific 
T cells (96), and different microorganisms have been suggested to influence 
pathogenesis, relapse and disease progression (99). Vaccines are another reported 
external trigger for the immune system; observational studies indicated an increased 
incidence of narcolepsy after the H1N1 influenza pandemic and vaccination 
campaign in 2009-2010 (100, 101), and molecular mimicry has been theorised as a 
possible explanation for these findings (102). 
The microbiota  
A microbiota is defined as an ecosystem of microbes residing on the mucosal 
surfaces of the human body that co-evolves with the human host in a symbiotic 




subunit of prokaryotes have recently replaced traditional culture-based techniques for 
characterizing microbial communities in any given sample (103, 104). However, the 
intestinal microbiota is currently the most studied and its overall composition 
depends on both genetic (105) and environmental factors (106). Oral, gut and skin 
microbiota could all affect the pathogenesis of systemic and organ-specific 
autoimmune diseases (107). For example, studies in mice indicate that the microbiota 
influences the gender bias in autoimmunity (108, 109). Microbes have the potential to 
activate different immune receptors, including TLRs, and induce signalling through 
the adaptor myeloid differentiation primary response gene 88 and the TIR domain-
containing adaptor inducing interferon-β (IFN), providing signals that both promote 
and inhibit autoimmunity (110, 111). Segmented filamentous bacteria have been of 
particular interest as they have the potential to breach the mucosal layers, interact 
with epithelial cells and, particularly through the induction of Th17 cells or Tregs, 
modulate host immunity and disease status (112, 113). Other suggested mechanisms 
through which microbiota promote autoimmunity are molecular mimicry and 
metabolic and epigenetic changes in host cells, especially histone acetylation 
controlled by microbial metabolites such as short-chain fatty acids (114, 115).  
The intestinal microbiota has also been described in cohorts of human patients 
with autoimmune diseases such as diabetes mellitus type 1 (116), MS (117, 118), 
rheumatoid arthritis (119), and SLE (120). Although a general autoimmune profile 
has not been proven, a common feature is reduced species diversity and altered ratios 
between major phyli (116, 117, 119, 120). The complexity of both the bacterial 
community and the host immune system makes it difficult to develop robust models 
to investigate the molecular mechanisms of this interplay in humans. Notably, both 
genetic and environmental factors that affect the immune system also modulate 
microbiota profiles and functions, which leads to an obvious question about the cause 
and effect of dysbiosis. Nevertheless, the microbiotas probably influence several 
diseases and contribute in the pathogenesis and phenotypes of autoimmune disorders. 
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1.4.6 Other potential modulators of autoimmunity 
Paraneoplastic syndromes are a heterogeneous group of systemic signs and symptoms 
caused by malignant cells and are most commonly found in patients with 
malignancies of the lungs, breasts, ovaries, or the lymphatic system. For example, 
bronchial carcinoids and small cell lung carcinomas are associated with the ectopic 
production of adrenocorticotropic hormone (ACTH), causing paraneoplastic Cushing 
syndrome (121). Moreover, a parathyroid hormone-related protein produced in 
malignant cells is the major mediator of humoral hypercalcemia in malignancy (122). 
Malignant cells may also display self-antigens that activate the immune system, 
leading to a break in immune tolerance, a phenomenon often seen in paraneoplastic 
neurological syndromes (123) where autoantibody production is also found (124). 
Pemphigus is another autoimmune disorder that is typically described as being part of 
a paraneoplastic syndrome (125). Interestingly, tumour resection and cancer 
treatment often cure the paraneoplastic disorders as well.  
 Epigenetic mechanisms such as DNA methylation, histone alterations, and 
RNA-based transcriptional control have the potential to regulate gene expression 
without changing the DNA sequence. Their sensitivity to external stimuli represent a 
link between environmental factors and genetics (126). Aberrant epigenetic patterns 
are described for several autoimmune diseases, suggesting a potential role in 
pathogenesis (127, 128). For example, impaired DNA methylation is found in T cells 
from human SLE patients (129, 130). Histone modifications in CD4+ T cells show 
significant alterations when compared to healthy controls and correlate with SLE 
disease activity (131). Noncoding RNA has also been proposed as a modulator of 
autoimmunity (132-134).  
Other cellular mechanisms may also contribute in the pathogenesis and 
development of autoimmunity. Dysfunctional endosomal and cytosolic receptors 
including TLRs have been linked to autoimmune disorders (135). The type I IFN 




arthritis and Sjögrens syndrome (136). Drugs targeting this pathway are currently 
being tested in clinical trials (137). Excessive production of type I IFNs is thought to 
affect both loss of tolerance and the autoimmune process in SLE (138, 139). Finally, 
because of the considerable sex bias characteristic of autoimmunity, with a higher 
incidence in females (140), gonadal hormones and direct X-chromosome effects are 




1.5 Autoimmune polyendocrine syndrome type 1 (APS-1) 
1.5.1 Diagnostic criteria and clinical features  
APS is a group of diverse clinical conditions collectively defined by an autoimmune 
functional impairment of multiple endocrine glands. APS can be further categorised 
into APS-1 and APS-2 (64). APS-2 is a common polygenic syndrome characterised 
by at least two of the three following endocrinopathies: diabetes mellitus type 1, 
autoimmune thyroid disease and primary adrenocortical insufficiency (PAI), whereas 
APS-1, or Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy 
(APECED, OMIM 240300), is a rare, childhood-onset, monogenic disease caused by 
mutations in the AIRE gene (141, 142). APS-1 affects both sexes equally and is 
reported to have a worldwide incidence of 1:100 000, with higher incidence among 
Persian Jews (1:9000) (143), Sardinians (1:14000) (144, 145) and Finns (1:25000) 
(62, 146). The syndrome is clinically defined by the presence of two of the three main 
components: hypoparathyroidism (HP), PAI, and chronic mucocutaneous candidiasis 
(CMC) (62, 64). The diagnosis can also be made upon identification of two disease-
causing mutations in AIRE together with clinical manifestations or on the basis of one 
main manifestation combined with a sibling diagnosed with APS-1 (64).  
The clinical picture of APS-1 is highly variable (Figure 3). Most patients 
present with one of the major disease components during childhood. HP is often the 
first endocrine manifestation, is the second most common component after CMC, and 
is present in about 80% of patients (145, 147-149). The onset of PAI normally occurs 
after CMC and HP, and it is reported in 60-80% of patients (145-148). Several other 
endocrine manifestations are also seen in APS-1 (64, 146, 150). Ovarian failure is 
frequently described (150), autoimmune hypophysitis and growth hormone 
deficiency have been reported (151), and autoimmune hypothyroidism is reported in 
about 30% (150). Pituitary failure and diabetes mellitus type 1 are uncommon (150), 






Figure 3. Homunculus illustrating the various manifestations of APS-1. 
The figure illustrates the different disease components of APS-1. The syndrome is clinically defined 
by the presence of two of the three main components: HP, PAI and CMC. However, the clinical 
picture is highly variable including several minor disease manifestations. The figure is adapted with 
permission from Husebye et al. (150). CMC, chronic mucocutaneous candidiasis; HP, 
hypoparathyroidism; PAI, primary adrenal adrenocortical insufficiency. 
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A wide spectrum of both autoimmune and non-autoimmune gastrointestinal 
manifestations has been reported in association with APS-1 (152). Autoimmune 
gastritis with pernicious anaemia is the most common of these disorders, and 
autoimmune hepatitis, which can be a serious complication, is often found in young 
patients (150), but prevalence varies across cohorts. Other gastrointestinal 
manifestations possibly associated with APS-1 are gallstones (152), celiac disease 
(153) and pancreatic insufficiency (146). Intestinal symptoms may be caused by an 
autoimmune enteropathy (152). Alopecia is the most common ectodermal 
manifestation (150, 154), and vitiligo may be one of the first signs of the syndrome 
(150). Nail dystrophy and enamel hypoplasia are other ectodermal components that 
seem to vary between populations (146-148). Periodic fever with urticarial rash is 
described as a frequent manifestation, especially in childhood (146, 148). Psoriasis 
and cutaneous vasculitis are described in case reports (155, 156). Finally, different 
ocular manifestations and a Sjögren’s like syndrome are reported (157-159).  
Several atypical and rare features are possibly associated with APS-1, 
including autoimmune destruction of the spleen (146) and haematological features 
such as autoimmune haemolytic anaemias, hypoplastic anaemias (146) and 
autoimmune thrombocytopenia; pulmonary manifestations such as bronchiolitis and 
interstitial lung disease (160-162); autoimmune tubulo-interstitial nephritis causing 
terminal renal failure (163, 164); and reversible metaphyseal dysplasia with growth 
retardation (165). Moreover, the neurological disorders inflammatory demyelinating 
polyneuropathy (166) and posterior reversible encephalopathy are reported as disease 
features of APS-1 (167). Recently, ptosis was also reported in the context of APS-1 
(168). 
Typically APS-1 presents with CMC and PAI before the age of 10, and all three 
main disease components are often observed before the age of 15 (64). Further 
disease manifestations may appear throughout life, although the precise timing and 




that commonly appear at young age are CMC, PAI, HP, urticarial eruption, hepatitis 
and intestinal dysfunction, whereas gonadal failure, diabetes mellitus type 1, vitamin 
B12 deficiency and gastritis are typically late manifestations (146-148). The overall 
rarity of the syndrome and its heterogeneity in phenotypic expression make it difficult 
to recognise, often resulting in delayed diagnosis (146-148, 150). Interestingly, recent 
findings from an American APS-1 cohort suggested adding the minor disease 
components urticarial eruption, intestinal dysfunction, and enamel hypoplasia to the 
diagnostic criteria to facilitate earlier recognition and diagnosis (148). The overall 
mortality rate is high (146, 169) and the most common causes of death are acute 
endocrine crisis and oral and esophageal squamous cell carcinomas (170).  
1.5.2 Chronic mucocutaneous candidiasis (CMC) in APS-1 
Most Candida species are opportunistic fungal pathogens that colonise the skin and 
mucosa of most healthy individuals without causing tissue damage or disease. 
However, several well-known factors increase susceptibility to Candida infections. 
Candida infections are, for example, common in neutropenic patients (171, 172) and 
patients treated with glucocorticoids or other immunosuppressive agents (173). 
Treatments with broad-spectrum antibiotics change the normal bacterial flora, 
eliminating natural antagonisms for fungal colonisation, which may lead to Candida 
infections (174), and prolonged hospitalisation of patients and damage to the skin or 
mucosal barriers increase the risk (174). Recent findings have also highlighted the 
influence of host genetics on susceptibility to Candida infections (17).  
CMC is defined as recurrent infections of nail beds, skin or mucosal surfaces. 
Oral Candida infections present clinically as creamy-white fungal plaques 
(pseudomembranous candidiasis), painful red lesions of the tongue (erythemaous 
candidiasis) or smooth or nodular lesions on any mucosal surface of the mouth 
(chronic hyperplastic candidiasis). The diagnosis of Candida infections depends on 
clinical signs and symptoms, growth of Candida in culture, and improvement of 
symptoms during anti-Candida therapy. CMC caused by C. albicans is the most 
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common and earliest manifestation in APS-1 and is reported to occur in 75-100% of 
patients (144-150). The clinical course of CMC varies from periodic to chronic; 
however, it usually affects the oral mucosa as angular cheilitis or the whole mouth as 
hypertrophic and/or atrophic lesions (146, 150, 175). Intestinal and invasive 
candidiasis is rare (146, 152), but Candida oesophagitis sometimes occurs (147).  
General resistance to mucosal fungal infections is thought to be T cell-
mediated at epithelial surfaces, particularly by Th17 cells (176) (Figure 1). Based on 
their specific cytokine profile (IL-17A, IL-17F, IL-21, IL-22, IL-26), Th17 cells have 
the potential to trigger production of neutrophil-recruiting and -activating cytokines 
and chemokines (e.g. granulocyte-colony stimulating factor and CXC chemokine 
ligand 8), pro-inflammatory cytokines (e.g. IL-6 and TNF-α) and anti-microbial 
peptides (e.g. defensins and S100 proteins) in many other cell types (177). The local 
environment controls the exact cytokine profile produced by Th17 cells via different 
receptors such as IL-23 or aryl hydrocarbon receptors (178). Both IL-17 and IL-17F 
are required for mucosal immunity, and IL-22 functions by critically regulating anti-
microbial genes, protecting epithelial surfaces and maintaining barrier integrity (179). 
Th17 cells have additionally been implicated in several autoimmune diseases by the 
observed induction of inflammatory responses and neutrophil recruitment (180, 181). 
Several studies have highlighted impaired immune functions in APS-1 
patients. Neutralizing autoantibodies against the Th17-cytokines IL-17A, IL-17F and 
IL-22 are suggested as a possible explanation for the impairment of mucosal 
immunity (182, 183). However, other studies have investigated immune mechanisms 
in response to Candida challenges in APS-1 patients, describing significant 
differences relative to healthy subjects. Data indicate that IL-22 producing cells are 
reduced in APS-1 patients, whereas the data regarding IL-17 production is 
inconsistent (183-185). Monocyte-derived DCs from APS-1 patients produce 
significantly more IL-2, IFN-γ, TNF-α and IL-13 compared to healthy controls and 




APS-1 patients, no significant association between genomic copy numbers of the β-
defensin cluster and susceptibility to CMC was found (187). Findings in a human 
monocyte model indicate that AIRE modulates the formation of fungal synapses and 
hyphal recognition and contributes in organising an effective immune response 
against C. albicans through an interaction with the Dectin-2 receptor and SYK 
signalling (188). Others have reported reduced numbers of CC chemokine receptor 6 
and CXC chemokine receptor 3-positive Th cells, CD16+ monocytes and Tregs in 
patients with APS-1 (189). However, expression levels of all PRRs involved in the 
defence against Candida, levels of plasmacytoid and myeloid DCs, and monocyte 
TLR2/6 expression are described as similar in APS-1 and healthy subjects (190). 
Collectively, these alterations in patients’ immune systems are likely to contribute to 
a phenotype of severe autoimmunity and susceptibility to CMC.  
Other factors possibly contributing to susceptibility to oral CMC in patients 
are reduced levels of antimicrobial peptides such as cystatin SA1 in saliva (191) and 
the fact that C. albicans isolates from patients show specific characteristics including 
strain specificity and resistance patterns (192-195). Mutations in the transcriptional 
activator of Complementary-determining region genes probably cause the azole 
resistance found in C. albicans isolates from patients (194). Interestingly, patients are 
often persistently colonised with C. albicans despite the relief of symptoms found in 
response to treatment.  
The clinical finding of severe CMC as a major disease manifestation in APS-1 
and the specific molecular immune defects described above clearly underpin immune 
deficiency as part of APS-1.  
1.5.3 Immunological features of APS-1 
Patients develop autoantibodies against molecular targets in affected organs and 
against components of the immune system. Organ-specific autoantibodies have 
proven to be excellent markers of organ manifestations, often preceding clinical 
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disease by years (196-198). Autoantibodies against type I IFNs and ILs involved in 
the Th17 immune response have been identified in almost all APS-1 patients and 
their development often precede onset of clinical disease, making their detection a 
suitable diagnostic tool (182, 183, 199-203) (TABLE 1).  
 
Table 1. Clinical manifestations and associated autoantigens in APS-1. 



































C-P450, C-P450-1A2, AADC, TPH 
TPH, HD, GAD 
 
(152, 197, 211) 



























(182, 183, 200) 
 
17OH, 17-hydroxylase; 21OH, 21-hydroxylase; AADC, aromatic L-amino acid decarboxylase; 
BPIFB1, bactericidal/permeability-increasing fold-containing B1; CMC, chronic mucocutaneous 
candidiasis; C-P450, cytochrome P450; C-P450-1A2, cytochrome P450 1A2; GAD, glutamic acid 
decarboxylase; HD, histidine decarboxylase; HP, hypoparathyroidism; IA-2, tyrosine phosphatase 
like protein; IF, intrinsic factor; IL, interleukin; INF-ω, interferon omega; KCNRG, potassium channel 
regulating protein; MAGEB2, Melanoma-associated antigen B2; NALP5, NACHT leucine-rich repeat 
protein 5; PAI, primary adrenal failure; PDILT, Protein Disulfide Isomerase-Like Testis Expressed; 
SCC, side-chain-cleavage enzyme; SOX, SRY-related HMG-box; TDRD6, Tudor Domain Containing 
6; TG, thyroglobulin; TGM4, transglutaminase 4; TH, tyrosine hydroxylase; TPH, tryptophan 




1.5.4 The autoimmune regulator (AIRE) gene  
The underlying cause of APS-1 is mutations in the AIRE gene. The AIRE gene is 
located at position q22.3 on chromosome 21 and contains 14 exons that encode a 
protein of 545 amino acids with a molecular weight of 57.5 kD (141, 142). The AIRE 
protein localises in the nucleus forming discrete dot-like structures (219) and 
harbours several functional domains typical for proteins involved in gene 
transcription (Figure 4). CARD is crucial for the homo- and multimerisation of AIRE 
(220), and the SAND domain (named after the protein Sp100, AIRE -1, NucP41/75 
and DEAF-1) mediates protein-protein interaction and DNA binding (221, 222). The 
plant homeodomain zinc finger motif 1 (PHD) is a histone code reader that 
recognises demethylated lysine 4 residues (223), while PHD2 is critical for 
interaction with protein partners involved in chromatin binding (224). The AIRE 
protein also contains a nuclear location signal (225) and four LXXL motifs (226). 
AIRE has its highest expression in a subset of mTECs (227, 228) characterised 
by the expression of MCH class II and the co-stimulatory markers CD80, CD86 and 
CD40 (229-231). In mTECs, AIRE acts together with several protein partners (232) 
regulating PGE (41), a process crucial for negative selection and deletion of 
autoreactive T cells from the repertoire (45). Without functional AIRE, autoreactive 
T cells with the potential to cause autoimmune disease are released to the periphery 
(Figure 2). Although AIRE’s function outside thymus has not been truly investigated 
and is not well understood, AIRE protein expression has been reported in human 
tissues such as lymph nodes, tonsils, gut-associated lymphoid tissues and the foetal 
liver (233), whereas AIRE mRNA transcripts are found in the spleen, B cells, 






Figure 4. The AIRE protein with its functional domains. 
AIRE acts as a transcription regulator, together with several protein partners, and has four major 
subdomains: the CARD/HSR domain, for caspase recruitment domain/homodimerisation domain or 
homogeneously straining region (amino acids 1-105); the SAND domain, for Sp100, AIRE-1, 
NucP41/75, DEAF-1 (amino acids 181-280); and the two plant homeodomain (PHD) zinc fingers 
(amino acids 296-343 and 434-475, respectively). The AIRE protein also holds four LXXLL domains 
with the potential to activate nuclear receptors (amino acids 7-11, 63-67, 414-418, 516-520, 
respectively) and a nuclear localisation signal (amino acids 100-189). The function of the different 
domains is given in the boxes below. The corresponding exons and amino acid numbers are given in 
the figure. The figure is modified from Bruserud et al. (235). 
 
In humans, AIRE mutations cause clinical APS-1 (235). Over 120 mutations 
have been reported (236) varying from single nucleotide substitutions to large 
deletions spread out across the coding sequence (235). This includes about 15 
mutations that affect mRNA splicing. The most common mutation worldwide is 
p.R257X/c.769C>T located in the SAND domain, whereas c.967_979del13, located 
in the PHD1 domain is the most common mutation in Norway (147), the British Isles 




described in Finland (p.R257X), Sardinia (p.R139X), Sicily (p.R203X), among 
Persian Jews (p.Y85C) and in Italy (p.W78R) (143, 145, 240, 241), all areas with a 
generally higher prevalence of the syndrome. AIRE mutations are typically passed on 
through autosomal recessive inheritance. However, the mutation p.G228W in the 
SAND domain has been shown to be dominant (242), and several mutations within 
the PHD1 domain are found to suppress gene expression driven by wild-type (WT) 
AIRE in a dominant-negative manner (243). Notably, one dominant mutation can 
cause autoimmune disease, although these patients exhibit a milder phenotype 
relative to classical APS-1 (243).  
Significant correlation between phenotype and AIRE genotype has not been 
described except for the possible association of CMC with p.R257X (183) and low 
frequencies of PAI and CMC with p.Y85C (143). However, some associations 
between HLA class and disease components have been reported (244). Many single 
nucleotide polymorphisms (SNPs) in AIRE have been studied in human disease 
association studies, albeit with conflicting results (245). 
Recent studies have indicated potential influence of AIRE beyond APS-1 and 
autoimmunity. For example, the expression of AIRE protein has been verified in 
human breast cancer cells and seems to be a strong prognostic factor for relapse-free 
survival (246). In addition, keratin 17-dependent AIRE expression can be induced in 
human and mice keratinocytes and is required for timely onset of Gli2-induced skin 
tumorigenesis in mice (247). However, the potential role of AIRE in peripheral tissues 




2. Aims of the thesis 
The overall objective of this thesis is  
 To identify all Norwegian APS-1 patients, characterise the disease phenotypes, 
and use APS-1 as a model disease for studying immunological mechanisms of 
autoimmunity and CMC.  
The specific aims of this thesis are 
1. To describe the phenotypes of APS-1 among all known Norwegian patients; 
correlate the clinical features with autoantibody profiles and AIRE mutations 
during extended follow up; and search for and describe potential novel distinct 
entities of the syndrome (paper I, paper II). 
2. To scrutinise genotype-phenotype relationships and explain why the 
c.879+1G>A splice mutation results in a mild APS-1 phenotype (paper III).  
3. To find a molecular explanation for increased CMC susceptibility in APS-1 
(paper IV). 





3. Comments on methods 
Complete descriptions of all materials and methods are given in each separate paper 
(papers I-V). Additional comments and considerations regarding patients, materials 
and key methods and assays follow.  
3.1 Materials 
3.1.1 Patients (Papers I-V) 
Patients were recruited from departments of internal medicine and paediatrics in 
Norwegian hospitals and included in the nation-wide Norwegian Registry of Organ-
specific Autoimmune Diseases (ROAS). The ROAS was first established in 1996 
with particular interests in APS and Addison’s disease. Its biobank contains whole 
blood, sera, DNA, RNA, peripheral blood mononuclear cells (PBMCs), tears and 
saliva from patients. In addition, the registry contains clinical information regarding 
disease components, medical treatments, autoantibody profiles and genotypes. The 
process of updating and improving ROAS is continuously ongoing.  
A total of 52 APS-1 patients, representing all identified Norwegian APS-1 
patients as of 2016, were described in paper I. Among these were seven patients 
identified after their deaths who were determined to have had a high probability of 
undisclosed APS-1. The selection of patients for papers II-V was based on the 
patient’s AIRE mutations, clinical phenotype, and the availability of biological 
samples. In paper II, additional patients (two Finnish and one Israeli) were included 
for studying oral tongue malignancies. 
3.1.2 Healthy controls (Papers I-V) 
Healthy age- and sex-matched controls were recruited from the local blood bank at 
Haukeland University hospital. Whole blood was taken directly into TrueCulture 
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Tubes (paper IV), and PBMCs or plasma was isolated from heparinised blood using 
Ficoll-Paque PLUS and stored at -150 degrees Celsius and -80 degrees Celsius, 
respectively (papers I, III, IV). Healthy age- and sex-matched volunteers working in 
the hospital were recruited for saliva sampling for paper V. Complete procedures for 
sample processing are given in each paper.  
3.2 Methodological considerations 
3.2.1 Clinical characterisation (Papers I-V) 
All patients were invited for follow up at Haukeland University hospital in Bergen for 
a clinical assessment including hormonal status and autoantibody profiles. All 
patients were seen by a senior consultant in endocrinology who followed a standard 
protocol including esophagogastroduodenoscopy, chest x-ray and imaging of the 
spleen and kidneys. Endocrinopathies were diagnosed as previously described (62). A 
dental and oral examination was performed by an experienced dentist, who also 
collected the saliva samples analysed in paper V. The two Finnish patients and the 
one Israeli patient described in paper II were characterised by international 
collaborators. Even if standardised protocols were employed we cannot rule out some 
variation between physicians.  
3.2.2 Radio-ligand binding autoantibody assays (Papers I-V) 
Radio-ligand binding assays were used to screen patient sera for autoantibodies 
against 21OH, 17-α-hydroxylase, aromatic L-amino acid decarboxylase (AADC), 
glutamic acid decarboxylase 65-kDA isoform (GAD65), IFN-ω, IL-17, IL-22, 
melanoma antigen B2, NACHT leucine-rich-repeat protein 5, protein disulphide 
isomerase-like testis expressed, putative potassium channel regulator, side-chain-
cleavage enzyme (SCC), sex-determining region Y-box 10, transglutaminase 4, 
tryptophan hydroxylase 1 (TPH1) and tyrosine hydroxylase (TH). The assays were 




DNA (cDNA) clones of APS-1 antigens were transcribed and translated in vitro in 
the presence of 
35
S-labelled methionine. Radio-labelled proteins were 
immunoprecipitated with 5 µl serum in 96-well filtration plates. Autoantibody-
antigen complexes were immobilised to protein A Sepharose and radioactivity was 
measured in a liquid scintillation counter (197). Pooled human sera from healthy 
donors were used as a negative control, and the positive control was a previously 
analysed APS-1 serum with known medium-to-high antibody levels. Normal limits 
were given as three standard deviations above the mean of about 100 healthy 
controls. Samples were tested as duplicates, and index values were calculated as 
((count per minute (cpm) sample – cpm negative control) / (cpm positive control – 
cpm negative control)) x 1000. All reported autoantibody assays were performed in 
our laboratory. Sera from the same patients taken at different time points were 
analysed in the same experiment to avoid variations between assays. 
3.2.3 Enzyme-linked immunosorbent assays (Papers I, IV) 
In paper I, an enzyme-linked immunosorbent assay (ELISA) was used to screen 
patients’ sera for autoantibodies against parietal cell antigens (Euroimmun). Sera 
from all patients included in paper IV were screened for autoantibodies against IL-23 
using an “in-house” sandwich ELISA. Moreover, ELISA (R&D Systems, UK) was 
also used to assess immune mediators of special interest (IL-17A, IL-17F, IL-22, and 
IL-23p19) in paper IV, verifying the results from the TrueCulture whole blood assay 
(paper IV).  
3.2.4 AIRE sequencing (Paper I-V) and HLA allele typing (Paper I) 
All living patients were screened for AIRE mutations (paper I). The DNA sequencing 
of AIRE spanning the exon-intron boundaries was performed using standard methods, 
and copy number analysis was performed by duplex TaqMan real-time polymerase 
chain reaction (PCR) (249). The HLA genotyping was performed using sequence-
based SBT Resolver and Assign Software (Conexio Genomics). 
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3.2.5 Thymic 4D6 cell line assay (Paper III) 
Due to the lack of thymic tissue from human APS-1 patients and healthy subjects, a 
transfected cell line assay was used to investigate the effect of different AIRE-
mutations on the expression of AIRE-regulated genes. The human thymic epithelial 
4D6 cell line was cultured, plated, and transfected with the current plasmids (AIRE 
without exon 7, c.769C>T/p.R257X and c.932G>A/p.C311Y in the pCMV6 vector) 
using the Fugene HD transfection reagent (Promega Corporation). Cells were further 
incubated for 24 hours, total RNA was extracted and cDNA prepared. AIRE-
regulated genes (keratin 14 (KRT14), IGF-like family member 1 (IGFL1)) were 
analysed by quantitative PCR (qPCR) and compared to the expression of the AIRE-
independent genes cyclin H and protein arginine methyltransferase 3. Beta2-
microglobulin (B2M) was used as an endogenous control. The fold difference was 
calculated based on the cycling threshold (Ct) values as 2^(Ct((target gene) – 
Ct(B2M)) – (Ct(test sample) – Ct(calibrator sample))), with the test sample defined as 
the current mutation and the calibrator as WT AIRE. The assay was repeated two to 
four times, and the results shown (paper III) are the mean values of these replicates.  
3.2.6 Immunoflourescence (Paper III) 
The transfected 4D6 cell line assay was also used to investigate the cellular 
compartmentalisation of mutant AIRE protein without exon 7 (paper III). Cells were 
plated in a 6-well plate containing sterile cover slips and incubated overnight, 
transfected with current plasmids, and incubated for another 24 hours. Cover slips 
with cells were then washed with phosphate-buffered saline (PBS) and fixed with 4% 
formaldehyde and washed again. Cells were then permeabilised with 0.5% Trioton-X, 
washed, and incubated for one hour at room temperature with 10% fetal bovine serum 
in PBS. Another washing step was performed before staining with phycoerythin 
conjugated anti-DYDDDDK (clone L5, BioLegend) in 1% bovine serum albumin in 
PBS for one hour at room temperature. Cover slips were then washed in PBS 




antifade reagent with DAPI (4’,6-diamidino-2-pheylindole). Slides were incubated 
for 24 hours in the dark at room temperature and analysed using a Leica SP5 
microscope. 
3.2.7 Whole blood stimulation assays (Paper IV) 
Whole blood assays probably mirror the in vivo conditions of immune activation and 
inflammation more precisely than cell assays considering the crosstalk between 
immune cells and the distribution of soluble mediators. Therefore, a TrueCulture 
whole blood assay (Myriad, RBM, US) was chosen to investigate immune activation 
after the Candida challenge in APS-1 patients. Whole blood was taken directly into 
TrueCulture collection and culture tubes, which contained either the supplied media 
(baseline) or media supplemented with Candida antigens (ATCC 10231). After 48 
hours of incubation, the supernatants were frozen and sent to Myriad RBM’s testing 
laboratory for analysis. The multiplex immunoassay Human InflammationMAP 1.0 
panel (Myriad, RBM, US) was used for analysing 46 unique analysts or biomarkers 
of immune activation. Thus, each individual patient and healthy subject became their 
own control when comparing baseline and stimulated levels of immune mediators. 
3.2.8 PBMCs stimulation experiments (Paper IV) 
A cell assay was designed to investigate IL-23p19 production in monocytes. 
Cryopreserved PBMCs were cultured overnight, and immune stimulation and 
activation of monocytes was induced by adding the Dectin-1 agonist beta-1,3-glucan 
to the cultures. After the period of incubation, cells were washed and stained for the 
surface marker CD14 and the intracellular IL-23p19 and analysed on a Becton 
Dickinson Fluorescence-activated cell sorter Accuri C6 flow cytometer. Individual 
populations were gated according to forward scatter, side scatter and specific 




 To be mentioned, few monocytes produced IL-23p19 upon simulation with the 
beta-1,3-glucan and some cells were borderline positive for IL-23p19 after 
stimulation. However, we carefully optimised our assay regarding incubation period, 
concentration of beta-1,3-glucan and Brefeldin A stimulation. Samples from patients 
and controls were always analysed in parallel, and a consistent gating strategy was 
used. 
3.2.9 Saliva collection (Paper V) 
All saliva samples were collected by the same experienced dentist and were collected 
between 9 a.m. and 11 a.m. Participants were asked to not brush their teeth, eat or 
drink for at least two hours before sampling. No participants were regular smokers or 
had received antibiotics within the last month before sampling. Samples were 
immediately stored at -80 degrees Celsius until analysed. Unstimulated saliva flow 
rate was estimated based on a time period of 15 minutes. 
3.2.10 High-throughput 16S ribosomal RNA sequencing (Paper V) 
The hypervariable region of the 16S ribosomal RNA (rRNA) is highly conserved 
between different species of bacteria making sequencing techniques suitable for 
assessing the bacterial content of any given sample. This technique is superior to 
culture techniques as it recovers both cultivated and not-yet-cultivated bacteria. High-
throughput 16S rRNA sequencing was therefore used to profile the oral microbiota in 
APS-1 patients and healthy controls. In brief, DNA was extracted from unstimulated 
saliva samples and the hypervariable regions V1-V2 were amplified using PCR, then 
sequenced on a 454 GS Junior System (Roche, Brandford, CT).  
3.2.11 Statistical considerations (Papers I-V) 
Sample sizes in most papers were relatively small and data did not always follow a 
normal distribution. This determined the statistical methods used. Data that did not 




whereas t-tests was used for normally distributed data (papers III-V). The Fischer’s 
exact test was used when comparing categorical data of small sample sizes (paper I). 
The Spearman’s rank correlation coefficient was calculated for correlation analyses 
(paper I). The level of significance was defined as P values less than 0.05. These 
statistical analyses were performed using IBM SPSS Statistics 22/23 or Prism 7 
(Graph Pad Software, Inc., San Diego, CA, USA).  
In paper IV, hierarchical cluster analyses were performed using J-Express 
(MolMine AS, Bergen, Norway). The alterations analysed were standardised after the 
ratio after/before stimulation and log(2) transformed before unsupervised hierarchical 
clustering with squared Euclidean distance measure with weighted average linkage 
was performed.  
In paper V, a bioinformatics pipeline was used to analyse the pyrosequencing 
reads of the 16S V1-V2 rRNA. Raw sequence reads were subjected to a species-level, 
reference-based taxonomy assignment. The Quantitative Insight Into Microbial 
Ecology pipeline software package version 1.9.1 was used for downstream analyses. 
A statistical method introduced in Metastats (http://cbcb.umd.edu/software/metastats) 
was then used to reveal significant differences between the oral microbiota in APS-1 
patients and healthy controls. For these latter analyses, Bonferroni Correction for 
multiple testing was included to avoid type I errors (false positives). 
3.2.12 Ethics (Papers I-V) 
All patients and healthy controls signed informed consent approved by The Regional 
Committee for Medical and Health Research Ethics. All studies included in this thesis 
were conducted in accordance with the Declaration of Helsinki and approved by The 
Regional Committee for Medical and Health Research Ethics (Biobank FOAS: 
2013/1504. Projects: 2009/2555, 2010/2069, 047.96).  
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4. Summary of results 
4.1 Paper I: “A Longitudinal Follow up of APS-1”  
The aim of this first paper was to describe the phenotype of all Norwegian APS-1 
patients based on extended follow up (1996-2016) and correlate the clinical features 
of APS-1 with autoantibody profiles and AIRE mutations.  
Fifty-two patients (24 females, 28 males) from 34 different families from all 
parts of Norway were identified. The phenotypes were highly variable, even among 
members of the same family. However, most patients had presented with one of the 
major disease components during childhood, and hypoparathyroidism and CMC were 
the most common initial manifestations. Overall, CMC (77%), enamel hypoplasia 
(72%) and hypoparathyroidism (73%) were the most frequent features. Forty percent 
of patients presented with the classical triad and 67% of these had developed all three 
major manifestations before the age of 25 years. With age, most patients exhibited 
three to five disease manifestations. A minority had milder phenotypes diagnosed in 
adulthood. Fifteen patients died during follow up or were deceased siblings with a 
high probability of undisclosed APS-1. The major causes of death were malignancies 
and adrenal and hypocalcemic crises. 
IFN-ω autoantibodies were found in all patients except three, and all had 
organ-specific autoantibodies. Autoantibodies against 21OH and SCC were 
significantly correlated with PAI (p<0.001 and p=0.002, respectively); autoantibodies 
against IL-22 were correlated with CMC (p=0.004); and autoantibodies against 
AADC were correlated with vitiligo (p=0.047).  
The most common AIRE mutation, c.967_979del13, and three patients had 
mono allelic AIRE mutations located within the PHD1 domain. Patients with the 
splice mutation c.879+1G>A all displayed a mild phenotype. None of the APS-1 




DQ8, and three out of four diabetes patients carried the DQB1*0602 allele, which is 
otherwise extremely rare in type 1 diabetes.  
Taken together, we found that the Norwegian patients present variable 
phenotypes where non-endocrine components such as CMC and enamel hypoplasia 
are common. Diagnostic workup using autoantibody analyses (e.g. IFN-ω) and AIRE 
sequencing to reveal APS-1 is highly recommended. Treatment is complicated and 
mortality is high. Structured follow up should be performed in a specialised centre. 
4.2 Paper II: “Oral Tongue Malignancies in APS-1”  
In this study, we aimed to clinically describe oral tongue malignancies in the context 
of APS-1. Together with international collaborators, we present a case series of four 
APS-1 patients from Finland, Norway, and Israel with oral tongue malignancies, an 
entity not previously described in detail. All patients presented disease-causing AIRE 
mutations and a typical APS-1 phenotype including severe CMC from childhood. 
One patient smoked on a daily basis, and two patients reported regular alcohol 
consumption. With the exception of early onset, the clinical presentation and the 
tumour histology were similar to other non-APS-1 patients with oral malignancies. 
However, they were treated with radical surgery resection alone or in combination 
with chemo-radiotherapy, or photodynamic therapy in one case. One patient died 
after recurrence of the tumour, while the remaining three patients are still under 
careful surveillance.  
This case series describe oral tongue malignancies as a novel disease 
component of APS-1. Oral manifestations should be properly investigated to reveal 
early signs of oral malignancies including tongue carcinomas. Moreover, aggressive 
CMC treatment and elimination of additional risk factors are important to avoid the 
development of oral malignancies in patients. 
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4.3 Paper III: “The AIRE mutation c.879+1G>A display a 
mild phenotype and alternative mRNA splicing in patients 
with APS-1” 
In this paper, we report four Norwegian APS-1 patients with the splicing mutation 
c.879+1G>A affecting the splice donor site of intron 7; all patients exhibit a mild 
phenotype compared to that of classical APS-1. Mini-gene analyses, with PCR and 
sequencing of AIRE mRNA transcripts in PBMCs from patients, reveal an altered 
splicing pattern including both normal transcripts and transcripts skipping exon 7. 
However, family members that were heterozygous carriers of the mutation presented 
with neither APS-1 manifestations nor typical autoantibodies in sera. Normal 
transcripts were consistently found in healthy controls. Using a transfected thymic 
cell line assay (4D6 cells) and qPCR, we demonstrated that the AIRE polypeptide 
deleted for exon 7 has the potential to induce AIRE-regulated genes (KRT14, IGFL1). 
Visualised by confocal microscopy, the AIRE polypeptide deleted for exon 7 show a 
similar nuclear localisation and dot formation typically described for WT AIRE and 
has the potential to co-localise and interact with WT protein. WT transcripts in 
patients are probably less than 50% as all patients display a definite APS-1 
phenotype. However, the occurrence of normally spliced AIRE together with an 
alternatively spliced AIRE polypeptide with some residual AIRE function, probably 
prevent severe disease and contribute to the mild phenotype observed in these 
patients.  
4.4 Paper IV: “Altered Immune Activation and IL-23 
Signalling in Response to C. albicans in APS-1” 
The aim of this study was to investigate immune responses in APS-1 patients in 
response to C. albicans. Whole blood and monocytes were stimulated with C. 
albicans antigens and the immune activation was assessed using a multiplex 




APS-1 patients displayed significantly altered immune responses relative to 
healthy controls. When stimulating whole blood with C. albicans, patient samples 
failed to increase several essential ILs including IL-2, IL-17A, IL-22, and IL-23. 
Monocytes from patients also produced significantly less IL-23p19 upon stimulation 
with curdlan compared to healthy subjects (p=0.005). A significant difference was 
also detected when comparing the percent increase in IL-23p19+ monocytes 
(p=0.0193). No significant differences in the CD14+ monocyte levels were found 
comparing patients and controls. 
In summary, we found that APS-1 patients had significantly altered immune 
responses to C. albicans including dysregulation of IL-23p19 production in 
monocytes. This probably contributes to the selective susceptibility to CMC found in 
the majority of patients.    
4.5 Paper V: “Oral microbiota in APS-1”  
Increasing evidence suggests a potential role of skin, oral and gut microbiota in the 
pathogenesis of autoimmunity. No information exists regarding oral microbiota in 
APS-1. The aim of this study was to investigate the possible role of oral microbiota in 
the pathogenesis and phenotypic expression of APS-1 through assessment of the 
bacterial microbiota of whole saliva in APS-1 patients using high-throughput 
sequencing. 
Five different phyla were detected in APS-1 patients with DNA sequences 
predominately assigned to the phyla Firmicutes (60%), Bacteroidetes (15%), 
Proteobacteria (10%), Actinobacteria (6%), and Fusobacteria (8%). The proportion of 
bacteria belonging to the major phyla Firmicutes was higher (60% vs 41%, p=0.002) 
than in controls, while the proportion of those belonging to the phyla Bacteroidetes 
was lower (15% vs 28%, p=0.007). Streptococcus and Gemella were prevalent genera 
in APS-1. Overall, a reduction in the total number of bacterial genera and species was 
detected in APS-1 compared to healthy subjects.  
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These findings indicate a significant altered oral microbiota in APS-1 that may 
contribute to both the pathogenesis and the phenotypic expression in this syndrome. 
However, it remains unclear whether an altered microbiota causes disease 





5.1 APS-1 as a powerful model for immunological studies 
There are both challenges and benefits in studying monogenic diseases. The rarity of 
most monogenic diseases reduces the availability of both patients and biological 
samples. The Norwegian APS-1 patients described in paper I were geographically 
spread throughout the country and received regular follow-up care at local hospitals. 
The process of clinical characterisation, collection of biological samples and timing 
of experiments therefore had to be carefully planned to achieve the representative 
data needed for our studies. These processes depended on extensive collaborations 
with patients and their organisations, physicians, researchers, and technical staff, 
which was challenging and time consuming. Biological samples always had to be 
strictly prioritised, and samples from all patients were unfortunately not always 
available for all planned experiments. These issues have previously been overcome 
by broad international collaborations, for example the Finnish-German APECED 
Consortium (142) and projects that were part of the European Union’s Research and 
Innovation funding programmes (e.g. EurAPS). This should probably also be the 
approach for future studies using APS-1 or other rare monogenic disorders as models 
for studying immunological mechanisms. International collaborations are also 
beneficial for the further characterisation of APS-1 phenotypes, as illustrated in paper 
II, where oral tongue malignancies in selected patients from Norway, Israel, and 
Finland were collectively described as a novel disease component of APS-1. 
Moreover, organising patient information into nation-wide registries such as the 
ROAS standardises the characterisation of patients, improves follow-up routines, and 
generates novel longitudinal data (paper I). 
 Studying monogenic human disorders gives the opportunity to understand the 
genetic and immunological pathogenesis underlying clinical phenotypes. The 
principles of immunological tolerance have already been revealed through studies of 
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APS-1 and AIRE (250-252), and the molecular mechanisms have been further 
described through the development of various Aire knock-out mice models (45, 232, 
253). Although animal models of APS-1 have identified several targets of 
autoimmunity (216, 217, 254-259), there are remarkable differences in phenotype 
between human APS-1 patients and Aire deficient mice, probably because of species 
specific peculiarities (260-262). This underscores the importance of human studies 
and may also indicate that other factors, such as immunogens and environmental 
factors, contribute to the variable phenotypic expression seen in human APS-1 
patients. 
The investigation of human patient cohorts and the development of animal 
models together with the continuous development in immunological techniques will 
increase our understanding of genetic and immunological mechanisms involved in 
autoimmune diseases, and APS-1 has proven to be an excellent model. However, 
studying APS-1 patients with CMC has also increased our understanding of the 
genetic and immunological mechanisms underlying susceptibility to Candida 
infections, knowledge that could prove useful for future immunotherapeutic 
approaches. In addition, the potential role of AIRE in cancer development has 
recently been highlighted (246, 247) indicating that APS-1 and AIRE may have 
relevance beyond the field of autoimmunity and CMC. 
5.2 Phenotypic variation in APS-1 
Patients with APS-1 present with variable phenotypes ranging from mild to severe. 
Some variation in the frequency of disease components occurs among different 
cohorts, although longitudinal data is only available from Norwegian (paper I), 
Finnish (146), Sicilian (241), and Sardinian patients (145). The Russian APS-1 cohort 
is probably the largest and includes 112 patients (168). However, the American 
cohort displays more severe phenotypes, with early disease onset and a mean of nine 
disease components (148). Hypothyroidism was not found in Sardinian patients, but 




patients (240). Autoimmune hepatitis was found in only two Norwegian patients (4%) 
but was an early and serious manifestation in one third of the Sardinian (145) and in 
half of American patients (148). In a study of 23 Persian Jews with APS-1 (143), 22 
presented with hypoparathyroidism, while only four patients had oral CMC. 
Interestingly, Norwegian patients present with a variable phenotype where non-
endocrine components such as CMC and enamel hypoplasia are common. Dental 
examinations revealed enamel hypoplasia in 72% of Norwegian patients, making this 
a common feature, occurring more frequently than in other cohorts. Varying practice 
among clinicians may influence the phenotypes reported. However, inviting other 
clinical specialists to join the phenotypic characterisation and follow up of APS-1 
patients could reveal novel disease components and improve mapping of already 
well-known features. 
 APS-1 patients develop a wide range of typical autoantibodies against 
molecular targets. Defining autoantibodies is important in order to understand the 
mechanisms of autoimmune disorders as they are markers of cell-mediated 
autoimmunity. Autoantibodies are easily accessible in peripheral blood and are useful 
for clinical diagnosis. Prevalence of typical autoantibodies and their association with 
various disease components were investigated in a cohort of 90 Scandinavian APS-1 
patients (63). Autoantibodies against 21OH and SCC were associated with PAI, 
whereas hypogonadism was exclusively associated with reactivity against SCC (63). 
Autoantibodies against TPH and GAD65 were associates with intestinal dysfunction, 
and reactivity against TPH was shown to be the best predictor for autoimmune 
hepatitis (63). The association of 21OH and SCC autoantibodies with PAI has been 
verified in both the American (148) cohort and among Norwegian patients (paper I). 
In addition, reactivity against TPH, but not GAD65, was associated with intestinal 
dysfunction in American patients. Reactivity against AADC correlated with vitiligo 
in Norwegian patients (paper I). The majority of patients presented with 
autoantibodies against Th17 cytokines, which correlated with CMC (182, 183). In 
paper I, autoantibodies mainly remained positive over time, but, interestingly, 10 
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patients lost reactivity against 21OH, and fluctuation in indices were found for 
several other autoantibodies including TH, SCC, IL-22 and GAD65. 
The Norwegian cohort (paper I) represents a population with a greater genetic 
heterogeneity compared to the Finnish (146), Sardinian (145) and Sicilian (241) 
patient cohorts, which are all populations with strong founder effects. However, the 
only association between phenotypes and the AIRE genotypes previously described is 
a higher prevalence of CMC in patients with the mutation p.R257X compared to 
patients with other mutations (183, 244) and low frequencies of PAI in patients with 
p.Y85C (143). Interestingly, Norwegian patients harbouring the splicing mutation 
c.879+1G>A had a milder phenotype compared to classical APS-1, with a generally 
late disease onset and extended time intervals between onset of new disease 
components. The mutation is located in the splice donor site of exon 7, and AIRE 
mRNA transcripts in PBMCs from patients show an altered splicing pattern including 
normal transcript and transcripts lacking exon 7. AIRE polypeptide lacking exon 7 
has a potential to induce AIRE-regulated genes and exhibits nuclear localisation 
similar to that of WT AIRE (paper III) in a transfected cell line assay. This probably 
contributes to the mild phenotype seen in these patients and also indicates that altered 
mRNA splicing is dependent on specific AIRE genotypes and has the potential to 
modulate phenotypic expression in APS-1. 
In APS-1, PAI is associated with HLA-DRB1*03 and alopecia with HLA-
DRB1*04-DQB1*0302, whereas type 1 diabetes is negatively associated with HLA-
DRB1*15-DQB1*0602 (244). Among Sardinian patients, an association between 
HLA-DRB1*0301-DQB1*0201, liver-kidney microsome autoantibodies (anti-
CYP1A2) and autoimmune hepatitis is described (145). Ten Norwegian patients with 
PAI carried HLA class II alleles known to protect against PAI in the general 
population (HLA-DRB1*DQB1*0501-DQA1*01015; HLA-DRB1*1301-
DQB1*0603-DQA1*0103; HLA-DRB1*1302-DQB1*0604-DQA1*0102; HLA-




patients with PAI carried the HLA class II haplotype DR3-DQ2/DR4.4-DQ8 (paper 
I), which is by far the strongest known predisposing genetic factor for autoimmune 
PAI (263). Three out of four Norwegian APS-1 patients with type 1 diabetes were 
found to carry the DQB1*0602 allele, which is otherwise extremely rare in type 1 
diabetes. Notably, the number of patient samples analysed for HLA associations was 
relatively small, which may explain some of the inconsistency in these reports. 
Although AIRE mutations are a definitive contributing factor in APS-1 development, 
the highly variable phenotype may indicate that HLA genotypes and environmental 
factors also influence disease onset and progression.  
Several environmental triggers have the potential to modulate the pathogenesis 
of autoimmune disorders. As AIRE mutations and circulating autoantibodies are 
present before patients develop clinical features of APS-1 (200, 203), investigating 
the role of environmental triggers is particularly important for understanding disease 
onset and progression. Factors such as genetics, sex and diet directly affect the 
immune system, influencing the risk of autoimmunity. However, they may also 
indirectly affect risk through modulation of microbiota profiles and functions. 
Experiments in animal models have shown that changes in the microbiota can affect 
inflammation and disease severity (264-266). Paper V gives novel data on 
significantly altered oral microbiota in APS-1 patients. The most striking differences 
seen in patient microbiota were a higher proportion of Firmicutes and a reduction of 
Bacteroides, together with reduced species diversity, a pattern that has previously 
been described in the intestinal microbiota in several autoimmune diseases (116, 117, 
119, 120). At the genus level, Streptococcus and Gemella were increased in patients. 
Only a few studies have investigated gastrointestinal microbiota in APS-1 (267-269). 
APS-1 patients develop early and sustained responses to gut microbial antigens 
reminiscent of Crohn’s disease associated with Treg defects (269), and patients with 
gastrointestinal manifestations show significant enrichment in segmented filamentous 
bacteria (267). However, further investigation of oral, skin and gut microbiota in 
APS-1 could reveal associations between microbial taxa and disease components and 
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provide a better understanding of the possible links between microbiota composition 
and autoimmunity.  
 Based on the above, both genetic components and environmental triggers 
probably contribute to the highly variable phenotypic expression of APS-1. The TCR 
affinity of autoreactive T cells that escape negative selection due to lack of AIRE adds 
a stochastic factor that is also likely to be determinative for autoimmune responses in 
APS-1.  
5.3 CMC in APS-1 
Recent evidence indicates that genetic variation in the host plays an important role in 
susceptibility to Candida infections (17). Both monogenic primary 
immunodeficiencies and more common SNPs in genes of the immune system are 
associated with fungal infection. Studies of patient cohorts with severe and recurrent 
Candida infections have revealed several monogenic disorders associated with 
immunodeficiency and increased susceptibility to fungal infections. Most of these 
genes encode proteins critical for host defence against fungal infections (Figure 3). 
CARD9 is a central mediator in the anti-Candida host defence involved in 
downstream signalling of several PRRs (270), and homogenous mutations in this 
gene cause susceptibility to both mucosal and invasive Candida infections (10). 
Likewise, signal transducer and activator of transcription 1 (STAT1) is a signalling 
molecule downstream of both type I and type II IFN receptors (271), IL-23 receptor 
and IL-12 receptor (272), and mutations in this gene result in a primary 
immunodeficiency associated with Candida infections (273). Hyper IgE syndrome 
(274) is associated with Candida infections of the skin and can be caused by several 
different mutations, including mutations in STAT3 (275), dedicator of cytokines 8 
(276) and TYK2 (277). Mutations in IL-17RA and IL-17F are found in patients with 
otherwise unexplained CMC (278). IL12Rb1 deficiency has been linked to both 
mucocutaneous and invasive Candida infections and deletions in the CD25 gene 




including SNPs in TLR1 (280), TLR2 (281), TLR4 (282), IL-4 (283), IL-10 and IL-
12b (284) have been shown to influence susceptibility to Candida infections.  
In APS-1, most patients present with CMC in combination with an extreme 
autoimmune phenotype (146-148), and patients are probably almost persistently 
colonised with C. albicans (194). Neutralizing autoantibodies against immune 
signalling molecules probably represent a key factor in determining APS-1 patients’ 
susceptibility to CMC (182, 183, 285). However, recent findings in a murine 
oropharyngeal candidiasis model suggest that additional genetic or environmental 
susceptibility triggers are needed to precipitate clinical disease (286). Another 
longitudinal study of six APS-1 patients investigating the association between CMC 
and anti-cytokine autoantibodies questions the importance of their role in CMC in 
APS-1 because some patients with CMC lack these autoantibodies (287). The 
hypothesis in paper IV was that other immune mechanisms contribute to CMC in 
APS-1 patients, and this study reveals several significant differences in immune 
activation upon Candida challenge in patients compared to healthy controls. 
Collectively, these alterations have broad implications on the quality of patients’ 
immune response to Candida. Mediators involved in the crosstalk between innate 
immune cells and T cells, including IL-1β, IL-10, IL-12p40, IL-18, and IL-23, were 
all found to be significantly altered, indicating that several cellular mechanisms are 
potentially involved. Patients also failed to up regulate IL-17A and IL-23, which are 
critical for optimal host defence against cutaneous candidiasis (288).  
Other studies have also reported altered immunologic responses in subsets of 
immune cells from APS-1 patients (185, 186, 190, 289). Although controversial, an 
extrathymic role of AIRE is reported in monocytes where it interacts with CARD9, 
SYK, and Dectin-1 (290). AIRE also has the potential to regulate the STAT1 protein 
levels in CD14+ monocytes (291). In paper IV, we showed that monocytes from 
patients produce less IL-23 upon stimulation with the Dectin-1 agonist curdlan. The 
data included in this thesis, together with the studies discussed above, clearly indicate 
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that APS-1 patients have significantly altered immune responses to Candida antigens, 
which collectively contribute to the susceptibility to CMC found in these patients.  
Monogenic disorders are rare, and the vast majority of Candida infections are 
probably due to a combination of complex genetics and environmental factors. 
However, studying monogenic disorders including APS-1 will increase our 
understanding of the genetic mechanisms underlying Candida infections, which is 
crucial for the development of future immunotherapeutic approaches to patient 
treatment. 
5.3.1 CMC and malignacies in APS-1 
Most APS-1 patients presenting with malignancies are in their thirties and have 
metastatic disease at diagnosis (170). CMC and smoking are risk factors (170). 
Squamous cell carcinomas of the oral or oesophageal mucosa are the most frequently 
seen malignancies in APS-1 (146, 147); it has previously been disputed whether these 
malignancies are a complication or component of the syndrome (170). However, 
these malignancies definitely occur, in the context of APS-1, more frequently and 
with an earlier onset relative to the general population. Specific characteristics of C. 
albicans isolated from APS-1 patients (192-195) and long exposure to it might be 
carcinogenic (194). For example, C. albicans isolated from human APS-1 patients 
have the potential to produce mutagenic amounts of acetaldehyde (292), which has 
carcinogenic effects, and increased saliva concentrations associate with other risk 
factors such as tobacco smoking, alcohol intake, and poor oral hygiene. Studies in 
mice have suggested that autoreactive CD4+ T cells and chronic fungal infections 
cause inflammation and tissue injury, which further drive carcinogenesis (293). A 
contribution from inflammation and CMC is also underpinned by the consistent co-
localisation of mucositis and malignant lesions. This was the case for the patients 
described in paper II who all had severe CMC since childhood and developed oral 




Interestingly, recent findings indicate that AIRE may play a role in the 
development of malignancies in peripheral tissues without C. albicans exposure. For 
example, AIRE protein expression in human breast cancer cells are a strong 
prognostic factor for relapse-free survival (246) and AIRE expression in keratinocytes 
is associated with skin tumorigenesis in mice (247).  
5.4 Screening and diagnosis in APS-1 
The rarity of and highly variable phenotype in APS-1 makes the syndrome hard to 
recognise (paper I), often causing a significant delay in proper workup and diagnosis. 
It has previously been estimated that at least one child every other year is born with 
APS-1 in Norway (294), but only one child has actually been diagnosed the last 11 
years (147). The exact reason for this is unclear, but two possible explanations are 
that disease components are diagnosed and treated while the syndrome goes 
undiagnosed or that patients die during childhood without diagnosis, as indeed was 
observed in seven Norwegian patients (paper I). Unrecognised components of APS-1 
such as PAI, HP and diabetes mellitus type I may be fatal. Dissemination of 
information about ROAS, recommended screening and follow-up routines could be 
improved, aiming to reach more physicians, patients, and families. 
Based on published APS-1 cohorts, the following screening procedure/flow 
chart is suggested for screening and diagnosis in APS-1 (Figure 5) (64): Patients 
presenting with particularly suspicious manifestations should be considered for APS-
1 workup, and AIRE sequencing is recommended in patients presenting two of the 
three major disease components: PAI, CMC and HP. Screening for INF-ω 
autoantibodies should be considered if a patient presents with one of the suggestive 
manifestations CMC, PAI, HP, premature ovarian failure, enamel hypoplasia, 
periodic fever with rash in childhood, non-infectious keratitis or autoimmune 
hepatitis, especially at a young age. AIRE sequencing is recommended in all patients 
presenting with INF-ω autoantibodies. The detection of two disease-causing 
mutations in AIRE meets diagnosis criteria for “classical APS-1”, whereas one 
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dominant mutation indicates “non-classical APS-1” (243). If no mutations in AIRE 
are revealed, imaging for thymoma or/and RAG sequencing should be considered to 
search for a combined immunodeficiency or Omenn syndrome (295). Finally, if no 
mutations in AIRE or RAG are found, the patient probably has an “APS-1–like” 
clinical condition. When a patient is diagnosed, all siblings should be investigated, 
and the family should be offered genetic counselling. 
 
Figure 5. Flow chart for APS workup. 
Patients presenting with particular suggestive manifestations should be considered for APS-1 
workup including AIRE sequencing and IFN-ω autoantibodies screening. The detection of two 
mutations indicates the diagnosis of classical APS-1. If no mutations are found, imaging for thymoma 
or/and RAG sequencing should be considered, searching for combined immunodeficiency or Omenn 
syndrome. The figure is adapted from Husebye et al. (64). APS, autoimmune polyendocrine 
syndrome; CID, combined immunodeficiency; IFN, interferon, MG, myasthenia gravis; OS, Omenn 
syndrome; OSAD, organ-specific autoimmune disease POI, primary ovarian failure; RAG, 




5.5 Treatment and follow up of APS-1  
Treatment of APS-1 is complicated and needs to be optimised for each individual 
patient. However, it typically includes hormone-replacement therapy and specific 
treatment of complications. CMC should be treated aggressively using oral 
mycostatin and oral amphotericin (150). In addition, other risk factors for oral 
malignancies such as smoking and alcohol consumption should be identified and 
minimised. Treatment of HP requires oral vitamin D derivatives in combination with 
calcium and magnesium supplementation. Other manifestations including 
pneumonitis and hepatitis may require immunosuppressive treatment (64). 
Vaccination against pneumococcus, meningococcus, Haemophilus influenza type b, 
and influenza is recommended due to asplenia (64).  
Patients with APS-1 are at constant risk for developing new disease 
components throughout life, and most receive complex treatments. Therefore, 
patients should be followed every 6-12 month in a specialised centre by a senior 
consultant in endocrinology, experienced with APS. Other specialists such as 
dentists, gastroenterologists and paediatricians may be involved if needed. Patients 
should be screened for new disease components by a proper clinical examination and 
serum autoantibody analyses. An oral examination should be included, focusing in 
particular on CMC and the development of oral malignancies. 
Finnish APS-1 patients have reported impairment in quality of life based on 
general health, emotional well-being and vitality measurements (296). Overall 
mortality is increased (146, 169), and life expectancy probably depends on the 
severity of the disease, patient compliance, how they cope with disease components 




6. Final conclusions  
In accordance with the specific aims of this thesis, the following conclusions can be 
drawn:  
 Norwegian APS-1 patients present with highly variable clinical phenotypes. 
Most patients present with one of the major disease components during 
childhood, and enamel hypoplasia, HP and CMC are the most frequently 
observed features. 
 Malignancy of the tongue is a novel entity of APS-1 and is probably caused by 
longstanding, chronic inflammation of the oral cavity caused by CMC 
infections. Oral tongue malignancies in APS-1 have an early onset compared 
to other patients with oral malignancies. 
 All Norwegian APS-1 patients present with typical autoantibodies, where 
autoantibodies against IFN-ω are the most frequent, followed by 
autoantibodies against 21OH and IL-22. 
 The most common AIRE mutation in Norwegian APS-1 patients is 
c.967_979del13. 
 The AIRE mutation c.879+1G>A is associated with a mild phenotype and 
causes altered mRNA splicing patterns including mRNA transcript with exon-
skipping and normal transcripts. Transcripts with exon-skipping produce a 
protein with residual AIRE function.   
 APS-1 patients show altered immune activation in whole blood upon 
stimulation with Candida, relative to healthy controls. This includes the 
dysregulation of several cytokines including IL-2, IL-17A, IL-22, and IL-23. 
 Monocytes from patients produce significantly less IL-23p19 upon exposure to 
a Candida-specific antigen compared to monocytes from healthy subjects. 




 APS-1 patients have significantly altered oral microbiota, with a general 
reduction in the total number of bacterial genera and species. The proportion 
of the major phyla Firmicutes is higher and Bacteroidetes lower in APS-1 
patients compared to healthy subjects. 
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7. Future perspectives  
Monogenic diseases have proven to be excellent in vivo models for genetic and 
immunological studies. Studying APS-1 and AIRE has expanded our knowledge of 
central immunological tolerance and how negative selection of T cells takes place in 
the thymus. However, further development of immunological techniques, especially 
for the study of the human immune system in health and disease, is needed in order to 
understand human disease and translate results into clinical practice. In the following, 
some future perspectives are briefly discussed.   
 Published patient cohorts and case reports from different geographical areas 
add knowledge of both pathogenesis and phenotypic variation in APS-1. The obvious 
extension of paper I is the inclusion of more patients and extension of follow-up care. 
Compiling and comparing patients from different countries could both reveal novel 
disease components (paper II) and provide data to establish more robust correlations 
between clinical features, autoantibody profiles and AIRE mutations. 
 Although a mild phenotype seems to be associated with the c.879+1G>A 
splice mutation, genotype-phenotype relationships are not well described in APS-1. It 
could be of great interest to further explore the molecular mechanisms of splicing 
using AIRE as a model, beyond the findings described in paper III. The development 
of an animal model could be beneficial for further characterisation of the mechanisms 
involved in AIRE splicing. 
 Several immune mediators in whole blood from patients with APS-1 were 
found to be dysregulated when challenged by C. albicans (paper IV). Other mediators 
or pathways could be further investigated, for example, using intracellular flow 
cytometry. Significantly altered numbers of specific subpopulations of immune cells 
have already been reported in APS-1 (189). However, introducing new methods such 




mapping of immune cells subgroups in patients. Other areas requiring further 
investigation are the fields of epigenetics and metabolomics and the related 
mechanisms of trained immunity in the innate immune system. Such research would 
also add to knowledge about the mechanisms involved in both autoimmunity and 
immunity against Candida infections.      
 Novel data regarding the oral microbiota in APS-1 is presented in paper V. 
Our profiling should be reproduced in a larger cohort, and it would be interesting to 
also characterise the skin and intestinal microbiota of patients. Profiling a lager 
cohort of patients could allow the correlation of taxa to disease components, 
autoantibody profiles or AIRE mutations. 
 The rarity of APS-1 makes studying it complicated. There are relatively few 
patients, and the availability of biological samples is limited. An executive aim 
should therefore be to organize patients into larger, international patient cohorts, 
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Autoimmunepolyendocrine syndrome type 1 (APS1) isa monogenic disease, also known as autoimmune
polyendocrinopathy-candidiasis-ectodermal dystrophy
(OMIM no. 240300). Clinically, APS1 is defined by the
presence of two of the three major components: hypo-
parathyroidism, primary adrenocortical insufficiency
(PAI), andchronicmucocutaneous candidiasis (CMC) (1).
However, the syndrome also includes many less known
disease components, and the clinical presentation is highly
variable (2). One major manifestation combined with a
sibling with APS1 also qualifies for the diagnosis. The
disease usually presents in childhood and adolescence, but
many patients are not diagnosed until adulthood or not at
all (3). APS1 patients have an increased risk of cancer and
increasedmortality comparedwith the general population
(4).Thediagnosis canalsobemadeby finding twodisease-
causing mutations in the autoimmune regulator (AIRE)
gene together with clinical manifestations (5, 6). About
115 mutations have been reported so far (7). AIRE is al-
most exclusively expressed in the thymus (8) and plays a
crucial role in negative selection of self-reactive T cells and
development of regulatory T cells (9, 10).
The highest prevalence is found among Persian Jews
(1:9000) (11), Sardinians (1:14 000) (12), and Finns (1:
25 000) (1). The prevalence in Norway was previously
reported at 1:90 000 (3). Recently, patients with mono-
allelic AIRE mutations with dominant inheritance, char-
acterized by a later disease onset and often milder pheno-
types, were reported (13). These nonclassical forms may
be much more prevalent because monoallelic AIRE mu-
tations have a prevalence in the general population of
about 1:1000 (13).
Most patients have autoantibodies against autoanti-
gens expressed in the affected tissue (14), eg, the steroid-
ogenic enzymes 21-hydroxylase (21OH) in the adrenal
cortex and side-chain-cleavage enzyme (SCC) in the go-
nads and adrenal cortex. Recently, several novel autoan-
tigens have been identified using proteome arrays, includ-
ing the prostate-specific enzyme transglutaminase 4
(TGM4) associated with male infertility and prostatitis in
Aire-knockout mice (15, 16). Other autoantigens identi-
fied using this technique include protein disulfide isomer-
ase-like testis expressed (PDILT) and melanoma antigen
B2 (MAGEB2), which are both expressed in testicular
germ cells (17). In addition, almost all patients display
autoantibodies to interferons (IFNs) and interleukins (ILs)
(18, 19); they typically appear years before the corre-
sponding clinical symptoms. Mutational analysis and as-
say of anti-IFN- autoantibodies are suggested as diag-
nostic options (20).
Information on longitudinal follow-up of APS1 pa-
tients is sparse, with only a few series published (21–23).
Building onprevious surveys of theNorwegian cohort and
ourNationalRegistryofAutoimmuneDiseases (3, 24),we
here provide a longitudinal follow-up of the Norwegian
cohort spanning two decades and presenting the natural




Patients were recruited from departments of medicine and
pediatrics from hospitals in Norway and were included in our
National Registry ofAutoimmuneDiseases initiated in 1996 (3).
All fulfilled the diagnostic criteria for APS1 given above. The
Regional Committee for Medical and Health Research Ethics
approved the study, and all participants gave informed consent.
Definitions and clinical data
The patients were assessed at least annually, including hor-
monal status and autoantibody profiles. All patients alive were
screened for AIRE mutations. A dental and oral examination
was performed in 31 patients, and most patients underwent
esophagogastroduodenoscopy, chest x-ray, and imaging of the
spleen and kidneys. Endocrinopathies were diagnosed as previ-
ouslydescribed (1).Thediagnostic criteria forotherdiseaseman-
ifestations are given in Supplemental Table 1.
Autoantibody assays
Autoantibodies against 21OH, 17--hydroxylase (17OH),
aromatic L-amino acid decarboxylase (AADC), glutamic acid
decarboxylase 65-kDA isoform (GAD65), IFN-, IL-17, IL-22,
MAGEB2, NACHT leucine-rich-repeat protein 5, PDILT, pu-
tativepotassiumchannel regulator, SCC, sex-determining region
Y-box 10, TGM4, tryptophan hydroxylase 1, and tyrosine hy-
droxylase were assayed by radio-binding ligand assay as de-
scribed previously (15, 16, 25). All autoantibody assays were
performed in our laboratory, and sera spanning a time period
were analyzed in the same experiment to avoid between-assay
variations in the indices. Parietal cell antigen autoantibodies
were assayed by ELISA (Euroimmun).
Mutational analysis of the AIRE gene
DNA sequencing of AIRE spanning the exon-intron bound-
aries was performed using standard methods. Primer sequences
are available upon request. Copy number analysis was per-
formed by duplex TaqMan real-time PCR as previously de-
scribed (26).
Human leukocyte antigen allele typing
The sequence-based human leukocyte antigen (HLA) geno-
typing was performed using SBT Resolver and Assign Software
(Conexio Genomics).
Statistical analyses
Fischer’s exact test with two-sided significance performed in
a 2  2 contingency table was used (IBM SPSS Statistics 22),
testing each autoantibody against the presence of different dis-
ease components. Similarly, the associations between pheno-
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types, AIRE mutations, and different HLA alleles were tested.
Specifically, we also investigated the correlation between PAI in
APS1 patients and HLA class II risk genotypes for PAI in the
general population as defined previously (27).
Results
APS1 patients ascertained
Applying our diagnostic criteria and the National Reg-
istry of AutoimmuneDiseases, we included 52 individuals
(28 males, 24 females) from 34 families, including three
patients (SupplementalTable 2, familyXXIX,patients no.
45–47) with monoallelic AIRE PHD1 mutations (Table
1). These patients represented all knownNorwegianAPS1
patients. Fifteenpatients diedduring the follow-upperiod,
including sevenwhowere identified only after their death.
Most of the patients participated in two earlier surveys (3,
24), but 12 identified after 2007 (3) were added to the
current survey.
Clinical manifestations and the classic triad
The clinical picture was highly variable, even among
members of the same family. An overview of the preva-
lence of the most common disease components, including
sex distribution and age at presentation, is given in Table
2 and Supplemental Table 2. The most common initial
manifestations were hypoparathyroidism (17 patients,
32%) and CMC (13 patients, 25%), but other compo-
nents occasionally presented first.Amongpatientswith all
three major components, 14 (67%) had developed the
triadby25yearsof age. Ingeneral, thedisease components
increased in prevalence by age, although the time courses
differed markedly (Figure 1). The median number of dis-
ease components was five (range, one to eight) (Supple-
mental Figure 1).
Two-thirds of the patients with hypoparathyroidism
were diagnosed before the age of 15 years. One young
female patient (patient 38) died of seizures at age 3 years,
probably from undiagnosed hypoparathyroidism.
Thirty patients with PAI (91%) were diagnosed before
age 25 years, including 21 (64%) before the age of 15
years. Two young females died in acute adrenal failure
during the follow-up period (Supplemental Table 3).
The clinical course of CMC varied from periodic to
chronic. Fourteen patients (27%) developed CMC before
Table 1. Basic Demographics of the 52 Norwegian
APS1 Patients
No. of females/males 24/28
No. of families 34
Age at onset of first component, y 0–43 (median, 8.5)
Age at death (n  15), y 3–64 (median, 34)
AIRE mutations found (alleles, n  92) 92% (85/92)
Autoantibodies (n  45)
Organ specific 100% (45/45)
IFN- 93% (42/45)







Age at Onset, y
Classic triad
Hypoparathyroidism 73 (38/52) 18/20 9 (1–60)
PAI 63 (33/52) 11/22 13 (4–55)
CMC 77 (40/52) 15/25 7,5 (0–64)
All three 40 (21/52) 6/15 14 (4–64)
Other endocrine disorders
Gonadal failure 33 (8/24)a 8/0 18 (15–25)
Diabetes mellitus 8 (4/52) 1/3 33 (23–54)
Hypothyroidism 19 (10/52) 8/2 22 (13–51)
Skin disorders
Alopecia 31 (16/52) 5/11 19 (4–41)
Vitiligo 15 (8/52) 4/4 20 (15–51)
Gastrointestinal disorders
Pernicious anemia or vitamin B12 deficiency 15 (8/52) 4/4 38 (13–63)
Malabsorption 23 (12/52) 5/7 21 (10–39)
Autoimmune hepatitis 4 (2/52) 0/2 5,5 (0–11)
Eye disorders
Keratoconjunctivitis 12 (6/52) 1/5 22 (11–25)
Others
Enamel hypoplasia 72 (18/25)b 9/9
Nail dystrophy 13 (7/52) 3/4
Asplenia 16 (5/31) 2/3
a Percentage of female patients.
b Percentage of patients examined by dentist.
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age10years andonly three after the ageof30years. Eleven
had angular cheilitis at the time of examination and an-
other 10 reported previous episodes. Eight patients (15%)
were diagnosed with candida esophagitis, sometimes
without typical symptoms or coexisting oral candidiasis.
One patient (patient 34) developed stenosis of the esoph-
agus requiring endoscopic dilation. Twelve of the 31 pa-
tients examined by a dentist tested positive for Candida
albicansby culture.One patient (patient 51) suffered from
severe candida otitis.
Other endocrinopathies
Hypothyroidism was the third most frequent endocri-
nopathy followed by gonadal failure. No male hypogo-
nadismwas found. Diabetes mellitus type 1 was rare (n 
4) and had a relatively late onset.
Oral cavity and teeth
Six of 31 examined patients had extensive composite
dental restorations, most probably secondary to underly-
ing enamel defects. Another 18 (72%) had enamel hyp-
oplasia typical for APS1 (Figure 2),
and fivehadenamelhypomineraliza-
tion without enamel hypoplasia,
which could be of different etiology.
The enamel hypoplasia varied in ex-
tent and location. Nine patients had
gingivitis, and eight patients pre-
sentedpathologically low (below0.1
mL/min) unstimulated salivary flow.
Skin diseases
Vitiligowas variable in extent and
location, from spots to almost uni-
versal, but was not classified into
segmental or nonsegmental forms.
The timeofdiagnosis of alopeciawas
highly variable, and the clinical
picture varied from chronic to
periodical.
Gastrointestinal manifestations
Chronic diarrhea was interpreted
as malabsorption. Pernicious ane-
mia and vitamin B12 deficiency typ-
ically presented late but were also
seen in some young individuals (pa-
tient 51). Autoimmune hepatitis was
found in two young male patients
(patients 12 and 42). Generally, the
gastrointestinal manifestations were
of variable intensity and duration.
Ocular disease
Three patients had keratoconjunctivitis, two iridocy-
clitis, and one blepharoconjunctivitis. A female patient
(patient 43)was diagnosedwith optic neuritis at the age of
22 years.
Other manifestations
Two patients were diagnosed with tubulointersitial ne-
phritis. Patient 1 was diagnosed with IgA nephritis at age
15 years, and patient 17 presented with nephrotic syn-
drome at age 48 years. Biopsy showed local segmental
nephrosclerosis. Her kidney disease is now stable after
steroid treatment. Deafness was found in one female pa-
tient (patient 51).
The natural course
Most patients follow the classic course already de-
scribed forAPS1: the first disease component, often one of
the classic triad components, presented in childhood,with
additional disease components occurring at different time
intervals (Figure 1 and Supplemental Table 2). However,
Figure 1. Disease histories of Norwegian APS1 patients. The lines start at birth and end at death
(bracket) or at current age (). Age at appearance of disease component is indicated by a symbol
of the disease. Disease components of uncertain time of onset are listed at the end of the line.
The major disease components CMC, HP, and PAI are marked in red, blue, and green,
respectively. Al, alopecia; AS, asplenia; AT, hypothyroidism; Ca, cancer; DM, diabetes mellitus; E,
enamel hypoplasia/defects; G, hypogonadism; H, hepatitis; HP, hypoparathyroidism; K,
keratoconjunctivitis; M, malabsorption; N, nail dystrophy; P, pancreas failure exocrine; PA,
pernicious anemia; PS, psoriasis; TIN, tubule interstinal nephritis; V, vitiligo.
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only 14 of 21 patients developed the full triad before the
age of 25 years. Early onset was associated with a more
severe phenotype, and the disease components increased
in prevalence with age. Hypoparathyroidism, PAI, CMC,
and autoimmune hepatitis appeared early, whereas hypo-
thyroidism, B12deficiency, andpernicious anemiamainly
hada late onset. Furthermore, the vastmajority of patients
had enamel defects or hypoplasia, probably with onset in
adolescence.Atypical late presentations and long intervals
between components contributed to delayed diagnosis
(patients 30, 31, and 46).
Mortality and cancer
Fifteen patients died during the follow-up period, and
seven patients were identified after their death (Supple-
mental Table 3). The major causes of death were malig-
nant disease and adrenal and hypocalcemic crises. The
median age at death was 34 years. Supplemental Table 4
gives an overview of the different malignant conditions
found.
Distribution of autoantibodies
We assayed a large panel of autoantibodies related to
APS1, including the recently identified autoantigens
TGM4, PDILT, and MAGEB2 (Supplemental Figure 2).
All 45 patients tested presented organ-specific autoanti-
bodies. In total, IFN- autoantibodies were found most
frequently (42patients, 93%), followedbyautoantibodies
against 21OH(71%)and IL-22 (71%).Notably, the pros-
tate-specific antigenTGM4was found only inmales (Sup-
plemental Figure 2 and Supplemental Table 2). Assay of
autoantibodies over time revealed a pattern dominated by
stable positivity. However, 10 patients lost reactivity
against 21OH during the follow-up period, and fluctua-
tionof indiceswere found for several other autoantibodies
such as tyrosine hydroxylase, SCC, IL-22, and GAD65
(Supplemental Figure 3).
AIRE genotype vs phenotype
We detected AIRE mutations in 44 patients. Two had
no mutations or copy number variations. Six deceased
patients were not tested, but genotypes could be deduced
based on their siblings. The most common mutation was
c.967_979del13 found in 45% of the alleles, followed by
c.769CT, and c.8791GA (Figure 3 and Supplemen-
talTable2).We thengrouped themaccording togenotype,
namely patients homozygous for missense mutations (ge-
notype 1; seven patients), patients homozygous for mu-
tations giving a truncated protein (genotype 2; 32 pa-
tients), and patients with one missense mutation and one
mutation giving a truncated protein (genotype 3; five pa-
tients). The splicing mutations were included in group 1.
The two patients without mutations (patients 49 and 50)
were excluded. The median number of disease manifesta-
tions was five in all groups. However, patients with ge-
notype 1 had a later disease onset (median age, 19 years)
than genotypes 2 and 3 (median age, 7 and 11 years, re-
spectively). Among patients with genotype 2, 90% had
CMC, and 75% had PAI. All patients with asplenia had
genotype2.Three patients homozygous andoneheterozy-
gous for the splicingmutation c.8791CG (patients 29,
30, 31, and 48) presented a mild phenotype with late dis-
ease onset (Figure 3 and Supplemental Table 2).
Immunotype vs phenotype
Seventeen (49%)of the patientswith hypoparathyroid-
ism had autoantibodies against NACHT leucine-rich-re-
peat protein 5. Among patients with PAI, 93% had auto-
antibodies against 21OH, 63% against SCC, and 43%
against 17OH. All of the patients with autoantibodies
against 17OH also had autoantibodies against 21OH.
Both autoantibodies against 21OH and SCC correlated
significantly to PAI (P  .001 and P  .002, respectively).
Thirty patients with CMC (81%) had autoantibodies
against IL-22, giving a significant correlation (P  .004).
Autoantibodies againstGAD65were found in22patients,
including three patients with diabetes mellitus type 1.
Seven patients with vitiligo had autoantibodies against
Figure 2. Typical enamel hypoplasia in APS1. A, Hypomineralization
(white areas on front teeth) and enamel hypoplasia revealed by
horizontal hypoplastic bands. B, Severe enamel hypoplasia with loss of
normal enamel structure. C, Enamel hypoplasia varying in size and
location, affecting both front teeth and molars.
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AADC (88%), proving a significant correlation (P 
.047). Figure 4 presents a heat map with clinical manifes-
tations and previously reported correlated autoantibodies
grouped together.
HLA vs phenotype
The HLA class II genotype stratified to the risk of PAI
is given in Supplemental Table 2. However, 10 patients
with PAI had HLA class II alleles known to be protective
in the general population. We also found significantly
more alopecia in this group compared to the rest of the
cohort. None of the APS1 patients
with PAI carried the high-risk HLA
class II haplotype DR3-DQ2/
DR4.4-DQ8 (27).
Discussion
This longitudinal follow-upof the52
Norwegian APS1 patients demon-
strates the clinical variability from
very mild to severe disease, occur-
rence of new components over time,
and an overall increased mortality
from adrenal crisis and cancer. Den-
tal examination revealed that enamel
hypoplasia was present in most pa-
tients and, together with CMC and
hypoparathyroidism, is one of the
three most common manifestations.
Longitudinal data have previously
been presented from the Finnish, Si-
cilian, and Sardinian patient cohorts
(with 91, 15, and22patients, respec-
tively) (21–23), which all represent
populations with strong founder ef-
fects (21, 23). The Norwegian pop-
ulationdisplays a greater genetic het-
erogeneity and may therefore be
more representative for the situation
in most countries.
The clinical variationand rarityof
APS1 makes the syndrome hard to
recognize. Since our latest report in
2007, only one child has been diag-
nosed, which is unexpected because
we estimate that at least one child
every other year is bornwithAPS1 in
Norway (3). The reason is unclear,
but most likely disease components
are being recognized and treated,
whereas the syndrome goes undiag-
nosed. Alternatively, patients die during childhood with-
out diagnosis, as indeed was observed in seven of our pa-
tients. This underscores the importance of increased
awareness and early diagnosis.APS1 shouldbe considered
in all patients presenting one of the major clinical mani-
festations, especiallywhen it presents in childhood.More-
over, when a new patient is diagnosed, all siblings should
be offered genetic counseling.
Some variation in the frequency of disease components
occurs among APS1 cohorts. We report several with hy-
pothyroidism, which is also found in Apulian APS1 pa-
Figure 3. AIRE mutations in Norwegian APS1 patients. A, Overview of the identified mutations
and their frequencies. B, Location of AIRE mutations in Norwegian APS1 patients together with a
schematic representation of the AIRE protein and its functional domains. Boxes 1–14 represent
the exons, and the different mutations are given in the text boxes above. CARD/HSR, Caspase
recruitment domain/homodimerization domain (amino acids 1–105); NLS, nuclear localization
signal (amino acids 100–189); SAND, Sp100, AIRE-1, NucP41/75 (181–280), DEAF-1; L (LXXLL),
nuclear receptor-binding motifs (amino acids 7–11, 63–67, 414–418, 516–520); PHD, plant
homeodomain type zinc fingers (amino acids 296–343 and 434–475); PRR, proline-rich region
(amino acids 350–430).
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tients (28). However, hypothyroidism was not seen in the
Sardinian patients (23), although late onset cannot be ex-
cluded (2). Although autoimmune cause was not proved,
it is probably caused by autoimmunity given the propen-
sity for autoimmunity in APS1. Furthermore, autoim-
munehepatitiswas described as a serious and early feature
in 27% of the Sardinian patients (23), whereas we found
hepatitis in only two (4%). In a study of 23 Persian Jews
(11), 22 presented with hypoparathyroidism, and only
four patients had oral CMC. The Sardinian patients dis-
played the most severe phenotype, with a mean of seven
disease manifestations per patient and early disease onset
(23). Besides the differentAIRE genotypes, other immune
genes might potentially affect the phenotype (29), and en-
vironmental factors and varying practices among clini-
cians may also have influence.
Poorly treated or undiagnosed endocrinopathies as
part of APS1, especially PAI, hypoparathyroidism, and
diabetes mellitus type 1, can be fatal. Adherence to ther-
apy, especially in teenage patients, is challenging. An in-
creased death risk and altered cancer incidence pattern
have been described (4). Identifying risk factors for ma-
lignancies andminimizing these by treatment ofCMCand
avoidance of smoking are probably important (21). In
addition, pneumococcal vaccinationmustbeperformed in
patients with asplenia and should probably be offered to
all APS1 patients.
All of the Norwegian patients had organ-specific au-
toantibodies. Typically, the presence of autoantibodies
correlates to clinical manifestations but may appear years
before the corresponding clinicalmanifestation (3, 14, 18,
19). A correlation between gonadal failure and autoanti-
bodies against SCC is reported (14, 30), which was also
found in five of the nine female patients with gonadal
failure in this study. In total, SCC autoantibodies were
found in 21 patients. Autoantibodies against GAD65 are
normally known to correlate with diabetes mellitus type 1
(31), but this is not the case in APS1 (14). We found
GAD65 autoantibodies in three of four diabetic patients
and in 19 patients without diabetes. No correlation with
autoantibodies againstGAD65 and vitiligo ormalabsorp-
tion was found, in conflict with an earlier report (14).
However, autoantibodies against AADC correlated with
vitiligo, and autoantibodies against 21OH and SCC cor-
relatedwith PAI.Autoantibodies against the prostate-spe-
cific enzymeTGM4wereonly seen in themales, consistent
with a recent report (15).
We found antibodies against IFN- in a similar pro-
portion to that in other APS1 cohorts (21–23). These au-
toantibodies are often found in the earliest samples; they
persist for decades and show a high specificity for APS1
(19, 32). IFN autoantibodies can also be found in low titer
in diseases causing an increased IFN production (ie, sys-
temic lupus erythematosus, human immunodeficiency vi-
rus, and hepatitis C virus infections), as well as in myas-
thenia gravis (33). Two female patients did not present
AIREmutations or IFN- autoantibodies but fulfilled the
clinical criteria. They may have mutations either in the
regulatory parts of the AIRE gene or in other genes in the
same pathway, or they may be phenocopies. Another pa-
tient presented all three major disease components from
childhood and was compound heterozygous (c.22CT/
c.967_979del13) for two AIRE mutations, but autoanti-
bodies against IFN- were not found.
The cohort presented here is older and has a much
greater genetic heterogeneity compared to other APS1 co-
Figure 4. Heat map of clinical manifestations and autoantibodies in Norwegian APS1 patients. Family number and patient number are given in
the first two rows. A black square represents a disease manifestation, and a gray square represents positive autoantibodies. If the square is dotted,
the examination/analyses are not performed; a white square represents negative disease component/AIRE mutation/autoantibodies that are
tested for.
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horts. Of particular interest was the c.8791CG splice
mutation found in three homozygous patients (patients
29, 30, and 31), who all had ancestors in a particular
district of Western Norway. Their phenotypes were char-
acterized by late disease onset and generally a milder phe-
notype. The three patients had their first manifestation at
15, 19, and 23 years of age. The two patients with hypo-
parathyroidism developed hypocalcemia at 43 and 60
years of age. It is not known whether this implies that the
splice defect is not complete and that some residual AIRE
function is present.
We found 10 patients with PAI carrying HLA class II
alleles known to protect against PAI in the general popu-
lation (27). Patients in this group also had significantly
more alopecia (P  .05). In contrast, none of the APS1
patientswith PAI carried theHLA class II haplotypeDR3-
DQ2/DR4.4-DQ8, which is by far the strongest predis-
posing genetic factor for autoimmune PAI. Moreover,
three out of four patients with diabetes carried the
DQB1*0602 allele, which is otherwise extremely rare in
type 1 diabetes. Although many of these patients are rel-
atives, this indicates that the known risk stratification for
HLA is overridden by the effect of theAIREmutations, in
contrast to previous findings (29).
In conclusion, the increasing knowledge about clinical
variation,AIRE, and autoimmunity seems to expand and
redefine APS1. However, the diagnosis should be consid-
ered in all patients presenting one of the major clinical
manifestations, especially when it first presents in child-
hood. Nonendocrine components such as enamel hyp-
oplasia and CMC are common and should trigger further
diagnostic workup. Autoantibodies against IFN- are
usually present, but their absence does not exclude the
diagnosis. The AIRE gene should be sequenced if clinical
suspicion is high.When a patient is diagnosed, all siblings
should be investigated because late onset is common. We
recommend regular surveillance in a specialized center be-
cause it can reduce morbidity and mortality.
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Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) or
Autoimmune polyendocrine syndrome type-1 (APS-1) (APECED, OMIM 240300) is a
rare, childhood onset, monogenic disease caused by mutations in the Autoimmune
Regulator (AIRE) gene. The overall mortality is increased compared to the general
population and a major cause of death includes malignant diseases, especially oral
and esophageal cancers. We here present a case series of four APS-1 patients with
oral tongue cancers, an entity not described in detail previously. Scrutiny of history
and clinical phenotypes indicate that chronic mucocutaneous candidiasis and smoking
are significant risk factors. Preventive measures and early diagnosis are important to
successfully manage this potentially fatal disease.
Keywords: Autoimmune polyendocrine syndrome type 1, oral malignancies, chronic mucocutaneous candidiasis,
endocrinology, Autoimmune Regulator gene
INTRODUCTION
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) or Autoimmune
polyendocrine syndrome type-1 (APS-1) (APECED, OMIM 240300) is a rare, childhood onset,
monogenic disease caused by mutations in the Autoimmune Regulator (AIRE) gene. It is clinically
defined by the presence of two of the three main components: hypoparathyroidism (HP), primary
adrenocortical insufficiency (PAI), and chronic mucocutaneous candidiasis (CMC) (1, 2), but
several less known organ-specific manifestations are also part of the syndrome making the
clinical phenotype highly variable (2–4). The overall mortality is increased (5, 6) due to different
complications such as acute adrenal crisis (3, 5), severe pneumonitis with respiratory failure (7–9),
fulminant autoimmune hepatitis (4), and interstitial nephritis causing renal failure (10, 11).
Malignancies are not uncommon in APS-1, and squamous cell carcinoma (SCC) of the oral or
esophageal mucosa is the most common entity (3, 5). In a case series by Rautemaa et al., most
patients were in their thirties and had metastatic disease at diagnosis (12). In one of the cases the
carcinoma affected the tongue, and CMC and smoking were associated with the malignancies (12).
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Oral malignancies typically develop in middle-aged or
older individuals, often in the fifth or sixth decade of life,
and there is a well-established association between both
smoking and heavy drinking, and SCC (13–15). Other
disorders affecting the oral and gastrointestinal mucosa,
such as infections and atrophic gastritis, may also contribute
to the development of malignancies (16, 17). Notably, oral
leukoplakia has the potential of malignant transformation
(18). Oral tongue SCC is the most common type of oral
malignancies and its diagnosis is based on clinical examination
combined with proper imaging using computer tomography
(CT) or magnetic resonance imaging (MRI) together with
histology of a tissue biopsy. The primary treatment approach
for oral malignancies is wide surgical resection with clean
margins, as marginal infiltration is associated with risk of
recurrence and impaired survival (19, 20). Postoperative
treatment typically consists of radiotherapy or chemo
radiotherapy depending on the disease stage and surgical
outcome.
Recently, we have come across several APS-1
patients diagnosed with oral tongue cancers, which
seems to be a distinct entity associated with APS-1.
Here we highlight their clinical presentation, diagnosis,
treatment, and follow up. We also briefly discuss the
biological aspects of oral malignancies in the context of
APS-1.
BACKGROUND
Basic APS-1 characteristics of the patients including AIRE-
mutations are summarized in Table 1. In the following text, we
briefly describe each patient focusing on the onset, diagnosis, and
treatment of their tongue SCC.
TABLE 1 | Characterization of the APS-1 patients.
Pat.
no.
Sex DoB Age of
onset
Classic triad Other manifestations AIRE mutations Autoantibodies
1 F 1967 1 Hypoparathyroidism (1), Chronic
mucocutaneous candidiasis (3), Primary
adrenal insufficiency (16)
Enamel hypoplasia (6), hypogonadism
(13), Vitiligo (13), alopecia (27), vitamin
B12 deficiency (28), malabsorption (30),
diabetes mellitus type 1 (31), asplenism
(39), autoimmune thyroiditis (47)
R257X/R257X SCC, NALP5, INF-ω
2 F 1965 2 Hypoparathyroidism (2), Primary adrenal
insufficiency (5), Chronic mucocutaneous
candidiasis (10)
Enamel hypoplasia (5), alopecia (10),
hypogonadism (15), tubulointerstitial
nephritis (19), autoimmune thyroiditis (32)
R257X/R257X 17OH, SCC, NALP5,
IL22, INF-ω
3 M 1996 11 Primary adrenal insufficiency (11), Chronic
mucocutaneous candidiasis





4 M 1970 3 Hypoparathyroidism (5), Primary adrenal
insufficiency, Chronic mucocutaneous
candidiasis
Alopecia(3), hepatitis, vitiligo, asplenism A374G/A374G 21OH, TPO
The age at diagnosis for each disease component is written in parentheses. The age of onset denotes the age at which the first APS-1 main component appeared. Abbreviations:
21OH, 21-hydroxylase; 17OH, 17-α-hydroxylase; AADC, aromatic L-amino acid decarboxylase; DoB, date of birth; IL22, interleukin-22; INF-ω, interferon-omega; NALP5, NACHT
leucine-rich-repeat protein 5; Pat no, patient number; SCC, side-chain-cleavage enzyme; TPH1, tryptophan hydroxylase 1; TPO, thyroid peroxidase.
Patient #1
This Finnish female patient (born 1967) was diagnosed with
HP at the age of 18 months. She presented with CMC in
the mouth and esophagus from the age of three years; regular
antifungal medication had not been used. The APS-1 diagnosis
was established in early childhood by AIRE sequencing. She
has smoked regularly from the age of 14 years (currently 1–4
cigarettes a day), but only consumed 4–5 units of alcohol per year.
At the age of 37 years endoscopic esophagus dilation was
performed because of stenosis. At the age of 45 years she
presented with a 1 cm ulceration on the right side of the
tongue. Histology revealed locally invasive SCC of World Health
Organization (WHO) Grade 1 without positive neck nodes
(T1N0M0, Stage I). A radical resection was performed. No
postoperative radiotherapy was given. She is now disease free
after an uneventful five-years follow up.
Patient #2
This Finnish female patient (born 1965) was diagnosed with
HP at the age of two years and has had oral CMC since
the age of 10 years. The APS-1 diagnosis was made based on
clinical manifestations and confirmed byAIRE sequencing. Renal
transplantation was performed at the age of 24 years because a
tubulointerstitial nephritis causing end-stage renal failure. She
presented with particularly severe CMC infections from the age
of 40 years. The yeast was fluconazole and itraconazole resistant,
but amphotericin B sensitive, and she received local treatment
with this medication. She has never been a regular smoker and
reported current alcohol use of about four units per week.
At the age of 30 years she was diagnosed with carcinoma in situ
of the right side of the tongue and a radical surgical resection
was performed. However, a local recurrence of SCC (T1N0M0,
Stage I) occurred one year after the initial treatment and a
hemiglossectomy with a radial forearm free-flap reconstruction
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FIGURE 1 | Invasive squamous cell carcinoma in the mobile tongue of patient
#2 with APS-1 (x 200 magnification).Histological picture showed a well
differentiated SCC with a rich lymphocytic inflammatory infiltrate at the tumor
front.
was performed (Figure 1). No postoperative radiotherapy was
given. During follow up, several biopsies were taken revealing
dysplastic changes including signs of SCC in situ. Seven years
after the first diagnosis, microinvasive carcinoma was diagnosed
in the right mandibular gingiva in the region of molar 46–
47. The lesion was treated with photodynamic therapy (PDT)
with 5mm clinical margins. PDT was delivered as an alternative
postoperative treatment option due to the history of recurrent
multifocal SCC, assuming that repeated surgical resections and
conventional radiotherapy would have caused a higher risk for
further impaired oral function. During a 16-year follow up, two
granulomatotic gingival lesions have been resected 13 years after
the primary diagnosis; histology showedmild dysplasia, gingivitis
and fungal infection.
Patient #3
This Norwegian male patient (born 1996) presented with
autoimmune hepatitis and severe malabsorption during the
first year of life. He also had recurrent CMC infections
in early childhood. PAI was diagnosed at 11 years of age.
The APS-1 diagnosis was confirmed by AIRE sequencing.
His gastrointestinal manifestations have been treated with
mycophenolate mofetil and tacrolimus with a good response.
The patient has also been diagnosed with asplenism. He neither
smokes nor uses alcohol.
At the age of 21 years he developed severe glossitis and pain in
the tongue (Figure 2). A constantly elevated lymphocyte count in
peripheral blood was also present. Initial biopsy revealed stromal
inflammation and hyperkeratosis without signs of malignancy.
However, the pain continued and, 2 months later, new
biopsies showed areas with epithelial hyperplasia, hyperkeratosis
(Figure 3A), and stromal inflammation dominated of plasma
cells (Figure 3B), and invasive SCC with a various histologic
appearance fromwell (Figure 3C) to poorly differentiated lesions
FIGURE 2 | A picture of the tongue of patient #3 at time of diagnosis. The
patient presented with severe CMC, glossitis, and severe pain in the tongue.
Extensive, non-homogenous changes in the form of speckled leucoplakia
were observed covering the whole dorsal side of the tongue which was
sensitive and indurated at palpation and functionally compromised with limited
movements.
(Figure 3D) at five different locations. The invasive tumor
front showed non-cohesive cancer foci, tumor cords, and single
cells, indicating an aggressively invasive lesion (Figure 3E).
Hemiglossectomy and a reconstruction using a radial forearm
free flap were performed. Moreover, investigation of the surgical
specimen revealed metastasis into one lymph node (Figure 3F).
The tumor was classified as T3N1M0, Stage III. He received
postoperative cisplatin-based chemotherapy and radiotherapy
because of an incomplete surgical resection and has no signs of
residual disease after 7 months follow up.
Patient #4
This male patient with APS-1 (born 1970) was the son of Persian
Jews who were first cousins. He presented, at the age of three
years, with alopecia areata, which advanced during the next
4 years to alopecia totalis. HP was diagnosed at the age of
five. During the following years additional diseases developed
including PAI, vitiligo, bilateral cataract, keratitis, pernicious
anemia, hepatitis, and asplenism. He had CMC since childhood
and had numerous episodes of oral and oesophageal candidiasis
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FIGURE 3 | Histological images of several biopsies taken from the tongue of patient #3. (A) epithelial hyperplasia with hyperkeratosis (x 100 magnification); (B) stromal
inflammation dominated of plasma cells (x 200 magnification); (C) well differentiated SCC (x 100 magnification); (D) poorly differentiated SCC (x 100 magnification); (E)
Non-cohesive cancer foci, tumor cords, and single cells (black arrows) observed at the invasive front indicate a highly aggressive SCC lesion (x 200 magnification).
Note the lymphocytic inflammatory infiltrate toward the more central area of the tumor, but its lack at the very edge of the invasive tumor front; (F) Histological analysis
of the lymph nodes removed at the time of hemiglossectomy revealed squamous cell carcinoma metastasis spread to one lymph node (x 100 magnification).
which was treated with nystatin, ketoconazole and fluconazole.
There was no history of smoking or alcohol consumption.
At the age of 38 years, a 2 cm mass was observed on the
right side of the tongue. Biopsy revealed SCC. Partial glossectomy
with selective neck dissection was performed and postoperative
radiotherapy to the primary site and to the neck was delivered.
Unfortunately, two years later, the tongue tumor recurred.
Chemotherapy was initiated, but without effect on tumor growth
and the patient died a few months later due to Staphylococcal
aureus septicaemia.
DISCUSSION
We here report four APS-1 patients with oral tongue SCC at
a relatively young age treated with radical surgical resection
alone or in combination with chemo-radiotherapy, or PDT in
one case. All patients had severe CMC since childhood; some
in combination with other well-known risk factors for oral
malignancies such as smoking and alcohol use. Apart from early
onset, the clinical presentation and histology of the tumors was
similar to other patients with oral malignancies. Based on our
findings, a prevalence of oral tongue malignancies in the entire
APS-1 cohort can be estimated to about 1–2 percent. However,
our case series highlights the importance of aggressive CMC
treatment and regular follow up examination of the oral mucosa
in APS-1 patients.
All four patients presented in childhood with CMC as
part of their initial APS-1 manifestations, probably causing a
longstanding chronic inflammation in the oral cavity. CMC
is a common and early main manifestation of APS-1 (2, 21).
It usually affects the oral mucosa as angular cheilitis or the
whole mouth causing hypertrophic and/or atrophic lesions (4,
5, 21). In APS-1, the chronic inflammation of CMC changes
the microenvironment of the oral cavity causing gingivitis and
glossitis (3) and it is proposed that patients are almost persistently
colonized with Candida albicans despite the relief of symptoms
found in response to treatment (22). Oral mycostatin or oral
amphotericin B is recommended to manage oral CMC in APS-
1 to avoid the problem of drug resistance and the inhibition
of steroidogenesis associated with continuous use of azole
preparations (2). Studies in mice have suggested that autoreactive
CD4+ T cells and chronic fungal infections cause inflammation
and tissue injury, which further drive carcinogenesis (23).
Although a synergistic effect of other risk factors such as smoking
and alcohol use is possible, these factors were not prominent in
two patients (#3; #4) and only one patient (#1) reported to smoke
on a daily basis.
The third patient had severe CMC and glossitis. Initial
biopsies did not reveal malignancy but stromal inflammation
and hyperkeratosis. However, the clinical examination and visual
findings gave a strong suspicion of malignancy and repeated
biopsies showed SCC. This highlights the crucial role of the
clinical examination including a visual inspection of the oral
cavity which should be included in the regular surveillance of
patients with APS-1. Using endoscopes with a “narrow-band
imaging” modality to screen oral and pharyngeal mucosa should
be considered in postoperative follow up and in high risk patients,
as this tool seems to increase the detection rate of dysplastic and
carcinoma lesions (24). This case also points out the importance
of selecting the area for biopsy and that several biopsies might
be necessary in case of extensive non-homogenous mucosal
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changes, as for this patient where biopsies from different areas
showed a histological appearance varying from no dysplasia to
poorly differentiated carcinoma (Figure 3). No general histologic
feature predictive for carcinogenesis could be recognized.
Nevertheless, the clinical suspicion for malignancies should be
high to secure proper and timely diagnosis.
All our patients described here had typical APS-1
manifestations and disease-causing AIRE mutations. Recent
studies have investigated the potential role of AIRE in cancer
and malignancies. For example, the expression of AIRE protein
has been verified in human breast cancer cells and seems to be a
strong prognostic factor for relapse-free survival (25). Moreover,
in human and mice keratinocytes, AIRE expression is inducible
in a keratin 17-dependent manner which is required for timely
onset of Gli2-induced skin tumorigenesis in mice (26). However,
genome-wide gene expression profiling of tongue SCCs using
RNA-sequencing has not revealed AIRE expression (27, 28).
Another recent elegant study in mice showed thatAire-deficiency
decreased the thymic expression of phosphoribosyl-anthranilate
isomerase (TRP-1), which is a self-antigen in melanocytes and
a cancer antigen in melanomas (29). This leads to defective
negative selection of TRP-1-specific T cells and elevated T-cell
immune responses that were associated with suppression of
melanoma outgrowth (29). In addition, transplantation of Aire-
deficient thymic stroma was sufficient to confer more effective
immune rejection of melanoma in otherwise Aire wild-type
hosts (29). Taken together, AIRE probably has functions beyond
thymic negative selection of T cells and may play a role in the
development of malignancies. This also underpins the value of
APS-1 as a powerful model disease for studying immunological
mechanisms in both autoimmunity and malignancies.
CONCLUDING REMARKS
Oral manifestations in APS-1 should be properly investigated
to reveal initial signs of oral malignancies including tongue
carcinomas. This malignancy seems to be a hitherto undescribed
distinct entity associated with APS-1. CMC should be
aggressively treated, and the risk factors reduced, to avoid
development of oral malignancies in these patients. A regular
investigation of the oral cavity is recommended as part of the
annual follow up.
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Objective: Autoimmune polyendocrine syndrome type 1 (APS-1) is a rare, childhood 
onset disease caused by mutations in the autoimmune regulator (AIRE) gene. Chronic 
mucocutaneous candidiasis (CMC) is one of the three major disease components and 
is, to date, mainly explained by the presence of neutralizing auto-antibodies against 
cytokines [interleukin (IL)-17A, IL-17F, and IL-22] from T helper 17 cells, which are 
critical for the protection against fungal infections. However, patients without current 
auto-antibodies also present CMC and we, therefore, hypothesized that other immune 
mechanisms contribute to CMC in APS-1.
Methods: Whole blood was stimulated with Candida albicans (C. albicans) in a stan-
dardized assay, and immune activation was investigated by analyzing 46 secreted 
immune mediators. Then, peripheral blood mononuclear cells were stimulated with 
curdlan, a Dectin-1 agonist and IL-23 inducer, and the IL-23p19 response in monocytes 
was analyzed by flow cytometry.
results: We found an altered immune response in APS-1 patients compared with healthy 
controls. Patients fail to increase the essential ILs, such as IL-2, IL-17A, IL-22, and IL-23, 
when stimulating whole blood with C. albicans. A significantly altered IL-23p19 response 
was detected in patients’ monocytes upon stimulation with curdlan.
conclusion: APS-1 patients have an altered immune response to C. albicans including 
a dysregulation of IL-23p19 production in monocytes. This probably contributes to the 
selective susceptibility to CMC found in the majority of patients.
Keywords: autoimmune polyendocrine syndrome type 1, chronic mucocutaneous candidiasis, monocytes, il-17, 
il-22, il-23
inTrODUcTiOn
Autoimmune polyendocrine syndrome type 1 (APS-1) or autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy (OMIM 240300) is clinically defined by the presence of two 
of the three major disease components primary adrenal insufficiency, hypoparathyroidism (HP), 
and chronic mucocutaneous candidiasis (CMC) (1). However, the phenotypic expression of the 
2
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syndrome is highly variable and includes many minor disease 
components (2). All patients present auto-antibodies against 
autoantigens expressed in the affected tissue and/or against 
immune mediators (3–5). The autoimmune regulator (AIRE) 
gene is the disease-causing gene (6–8). AIRE acts as a transcrip-
tion factor and is almost exclusively expressed in the thymus 
(9), where it orchestrates the process of negative selection of 
self-reactive T  cells and contributes to the development of 
regula tory T cells (Tregs) (10, 11).
Candida albicans (C. albicans) is an opportunistic yeast, 
colonizing the skin and mucosa of most healthy individuals 
without causing tissue damage or disease (12). However, it may 
cause superficial mucocutaneous or systemic infections; often in 
individuals with impaired immune functions. In APS-1, CMC 
caused by C. albicans is the most common and earliest main 
manifestation (13) and is reported in 75–100% of patients (1, 4, 
14–17). The clinical course varies from periodic to chronic and 
usually affects the oral mucosa as angular chelitis, or the whole 
mouth with hypertrophic and/or atrophic lesions (1, 2, 13). 
Skin, nails, and genital mucosa in females may also be affected. 
Susceptibility to candidiasis maps to mucosal, not systemic, 
disease in APS-1 (1).
Interleukin (IL)-23 is required for differentiation, func-
tion, and maintenance of T helper 17 (Th17) cells, and this 
signaling axis plays a central role in host defense against 
cutaneous candidiasis (18). In APS-1, neutralizing auto-
antibodies against the Th17 cytokines, IL-17A, IL-17F, and 
IL-22, are suggested to explain the impairment in mucosal 
immunity (19, 20). Noteworthy, patients without auto-
antibodies also present CMC (4), and therefore, it remains 
disputable whether the Th17 cytokine-neutralizing auto-
antibodies are sufficient to precipitate CMC. To gain a better 
understanding of the molecular mechanism of CMC in 
APS-1, we investigated the immune activation in response to 
C. albicans in both whole blood and monocytes of patients 
finding a generally altered immune activation including a 
dysregulation in the IL-23/Th17 pathway.
MaTerials anD MeThODs
Patients and clinical Data
Patients (n  =  18) were included from our National Registry 
of Organ Specific Autoimmune Diseases and were previously 
described in the Norwegian cohort (4, 21, 22). All fulfilled the 
diagnostic criteria of APS-1 (2). Patients received appropriate 
hormone replacement therapy of endocrine deficiencies at physi-
ological doses. In HP, normal levels of calcium were maintained 
with oral administration of cholecalciferol and calcium. However, 
these treatments should not have significant immunomodulatory 
effects. None of the patients or healthy controls was pregnant, 
had acute infections, or received vaccinations at the time of 
sampling. An overview of the patients’ data is given in Table 1. 
Samples from all patients were not available for all experiments. 
Healthy age and gender matched controls (n = 31) were recruited 
from the local blood bank at Haukeland University Hospital. All 
participants gave informed and written consent, and the study 
was approved by The Regional Committee for Medical and 
Health Research Ethics for Western Norway.
Measurement of immune Mediators
In vitro production of immune mediators in response to 
C. albicans was characterized using the TrueCulture assay system 
(Myriad, RBM, USA). One milliliter of whole blood was taken 
from APS-1 patients (n = 11) and age- and sex-matched healthy 
controls (n = 13) into TrueCulture collection and culture tubes 
(Myriad, RBM) that contained either the supplied media (base-
line response) or media supplemented with C. albicans (ATCC 
10231; Myriad, RBM). Following a 48 h activation period at 37°C, 
the supernatants were frozen and sent to Myriad RBM’s testing 
laboratory where 46 unique analytes or biomarkers of immune 
activation were assessed using the multiplex immunoassay 
Human InflammationMAP 1.0 panel (Myriad, RBM). Mediators 
of special interests (IL-17A, IL-17F, IL-22, and IL-23p19) were 
also assayed with enzyme-linked immunosorbent assay (ELISA) 
(R&D Systems, UK) for all patients included in this experiment 
(n =  11) and an extended group of healthy controls (n =  19). 
These ELISAs were done on supernatants from the correspond-
ing TrueCulture tube. Standard sandwich ELISA was performed 
on sera from all patients (n = 18) searching for auto-antibodies 
against IL-23 (PeproTech, USA).
isolation and culture of cells
Peripheral blood mononuclear cells from APS-1 patients (n = 6) 
and healthy controls (n =  12) were isolated from heparinized 
blood by Ficoll-Paque PLUS (GE Healthcare) density gradient 
centrifugation and stored at −150°C. Cryopreserved periph-
eral blood mononuclear cells (PBMCs) were used in all cell 
experiments. PBMCs (106 cells/mL) were cultured overnight in 
RPMI-1640 medium (Lonza) supplemented with 10% human AB 
serum (Sigma, USA) and 1% penicillin–streptomycin (Sigma) at 
37°C with 5% CO2. For the immune stimulation and activation 
of monocytes, 10 μg/mL of the Dectin-1 agonist beta-1,3-glucan 
(Curdlan AL, InvivoGen, USA) was added to the cell cultures. 
Lipopolysaccharide from Salmonella abortus equi (Sigma-
Aldrich) in a concentration of 1 μg/mL was used as a non-Candida 
positive control for monocyte activation. The protein transport 
inhibitor Brefeldin A (BioLegend, USA) was added at 1 μg/mL 
90–120 min after the start of incubation.
Flow cytometry
After the incubation period, cells were washed with 2 mL buffer 
[phosphate-buffered saline (Sigma) containing 5% fetal bovine 
serum (Life technologies)] and centrifuged at 350 × g for 5 min. 
Cell surface staining of monocytes was done in 0.1 mL buffer for 
30 min on ice with fluorescein isothiocyanate-conjugated anti-
body to human CD14 (clone HCD14, BioLegend) at a dilution of 
1:20. Cells were then washed and fixed in 0.5 mL/tube Fixation 
Buffer (BioLegend) in the dark for 20 min at room temperature 
before centrifugation at 350  ×  g for 5  min and then washed 
again. The fixed cells were re-suspended in 0.1 mL Intracellular 
Staining Perm Wash Buffer (BioLegend) and stained with 
10 μL phycoerythrin-conjugated antibody to human IL-23p19 
(clone #727753; R&D Systems) in the dark for 20 min at room 





















c.967_979del13/c.769C>T Positive 21OH, IL-17, IL-22, TGM4
2 I M 1992 2 CMC(2), HP(4) K(11), M(15), E c.967_979del13/c.769C>T Positive AADC, GAD65, IL-17, IL-22,  
TGM4, TH




c.967_979del13/large del Positive 21OH, 17OH, IL-22, MAGEB2, 
NALP5, SCC, TH




Positive 21OH, 17OH, AADC, GAD65, IL-22, 
MAGEB2, NALP5, SCC, TH, TPH1




c.769C>T/c.769C>T Positive 21OH, AADC, IL-17, IL-22 MAGEB2, 
SCC, SOX10, TGM4
6 IV F 1960 9 HP(9), CMC Al(6), G(17),  
AT, E, N
c.22C>T/c.290T>C Positive NALP5, PCA
7 V M 1970 12 PAI(12), CMC(42) E c.967_979del13/
c.967_979del13
Positive 21OH, GAD65, IL-22, SCC
8 VI F 1974 23 PAI(23), CMC(23) E c.879+1G>A/c.879+1G>A Positive 21OH, 17OH, NALP5
9 VI M 1959 43 HP(43), CMC V(15), DM(32), 
E(49), AT(51)
c.879+1G>A/c.879+1G>A Positive 21OH, 17OH, AADC, GAD65,  
NALP5, TH, TPH1
10 VII M 1964 14 HP(14), CMC(22) DM(23), K(25), 
N(25), V(41), 
Al(41), E
c.769C>T/c.1249dupC Positive AADC, GAD65, IL-22, PCA,  
PDILT, TGM4, TH, TPH1
11 VII M 1963 nk CMC? E c.769C>T/c.1249dupC Positive AADC, IL-22, SOX10, TGM4
12 VIII F 1988 3 HP(3) AT(24), E, M c.967_979del13/
c.967_979del13
Positive NALP5
13 IX F 1987 2 CMC(2), HP(15) E(24), Al, E c.1163_1164insA/
c.1249_1950dupC
Positive 21OH, AADC, IL-17, IL-22,  
MAGEB2, NALP5, SOX10
14 X F 1971 5 HP(5) G(19), B12(35), 
M(39), E
c.934G>A/not found Positive NALP5, AADC, GAD, PCA




Positive 21OH, 17OH, NALP5, TH, TPH, 
AADC, GAD, SCC, MAGEB2,  
SOX10, PDILT, IL-22




Positive 21OH, SCC, TH, AADC, GAD,  
NALP5, TGM4, IL-17, IL-22
17 XII M 1958 Not 
known
PAI(55), HP, C Al, AS, E c.967-979del13/c.967-
979del13
Positive GAD, TPH, MAGEB2, IL-17, IL-22
18 XIII F 1982 5 CMC(3) V(15), PA(13),  
E, M
c.967-976del13/c.977C>T Positive AADC, GAD65, IL-22, PCA,  
PDILT, TPH1
Patient number, family, sex (M, male; F, female), YoB, clinical manifestations, AIRE mutations and auto-antibodies in APS-1 patients. The age of debut denotes the age at which  
the first APS-1 main component appeared. The age at diagnosis is written in parentheses.
21OH, 21-hydroxylase; 17OH, 17-α-hydroxylase; AADC, aromatic l-amino acid decarboxylase; Al, alopecia; AS, asplenism; AT, autoimmune thyroiditis; CMC, candidiasis; 
DM, diabetes mellitus; E, enamel hypoplasia; G, hypogonadism; GAD65, glutamic acid decarboxylase 65-kDA isoform; HP, hypoparathyroidism; IFNω, interferon-omega; IL-17, 
interleukin-17; IL-22, interleukin-22; K, keratoconjunctivitis; M, malabsorption; MAGEB2, melanoma antigen B2; N, nail hypotrophy; NALP5, NACHT leucine-rich-repeat protein 
5; PA, pernicious anemia; PAI, primary adrenocortical insuffiency; PCA, parietal cell antigen; PDILT, protein disulfide isomerase-like testis expressed; SCC, side-cleavage enzyme; 
SOX10, sex-determining region Y-box 10; TGM4, transglutaminase 4; TIN, nephritis; TH, tyrosine hydroxylase; TPH, tryptophan hydroxylase; V, vitiligo.
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temperature. Finally, another washing step was done before 
the fixed and stained cells were re-suspended in 0.3 mL buffer. 
Cells were analyzed on a BD FACS Accuri C6 flow cytometer. 
Individual populations were gated according to forward scatter 
(FSC), side scatter (SSC), and specific markers, and the data were 
subsequently analyzed with FlowJo X software.
statistical and bioinformatical analyses
Paired t-tests were used analyzing paired data, and the Mann–
Whitney U test was used when comparing groups. The level of 
significance was defined to a P value less than 0.05. Statistical 
analyses were performed using IBM SPSS Statistics 23 or Prism 
7 (Graph Pad Software, Inc., San Diego, CA, USA). Hierarchical 
cluster analyses were performed using the J-Express (MolMine 
AS, Bergen, Norway) (23), and the alterations analyzed were 
standardized after ratio after/before stimulation and log(2) 
transformed before unsupervised hierarchical clustering with 
Squared Euclidean distance measure with weighted average link-
age was performed (23). Functional annotation and generation 
of the basic framework of the network displayed in Figure S1 
in Supplementary Material were computed using ClueGO 2.3.3 
(24) within the Cytoscape 3.4.0 suite (25). Proteins that in APS-1 
patients failed to be up-regulated in response to C. albicans 
(P > 0.05) while found to be significantly increased in healthy 
controls upon C. albicans exposure (P  <  0.05) were entered 
as group 1. Group 2 includes SERPINA1 and GC, which were 
found significantly down-regulated in APS-1 patients but were 
unchanged in healthy subjects when responding to C. albicans 
stimulation. These two groups were interrogated regarding 
their associations with a  priori-defined biological terms com-
prised in the complete biological process gene ontology (GO) 
(GO:0008150; 23.02.2017). The analysis settings were (i) hits 
Mediator autoimmune polyendocrine 
syndrome type 1
controls
response to  
C. albicans




c3 → ns (0.661) ↑ 0.030
F7 → Ns (0.060) → Ns (0.101)
Fga → ns (0.450) ↑ 0.011
vWF → Ns (0.807) → Ns (0.464)
serum proteins
B2M → ns (0.637) ↑ 0.024
FTL ↑ 0.002 ↑ <0.001
HP → Ns (0.562) → Ns (0.967)
Traditional markers
CRP → 0.124 → 0.725
Others
gc ↓ 0.037 → ns (0.974)
serPina1 ↓ 0.028 → ns (0.683)
IL1RN ↑ <0.001 ↑ <0.001
KITL ↑ 0.002 ↑ <0.001
TIMP1 ↑ 0.017 ↑ <0.001
TNFRSF1B ↑ <0.001 ↑ <0.001
The table gives the mediators analyzed in the TrueCulture system and the response to 
C. albicans in both patients and healthy controls. T-test for paired data was used for 
statistical comparison. ↑ indicates a significant up-regulation, ↓ indicates a significant 
down-regulation, and → indicates no significant change in the mediator concentration. 
Mediators with a significant different response in patients and controls are marked bold.
Nd, not detectable; Ns, not significant.
aIL-22 was not included in the TrueCulture system but analyzed with enzyme-linked 
immunosorbent assay.
Table 2 | Change of different immune mediators in response to Candida 
albicans in patients and controls.
Mediator autoimmune polyendocrine 
syndrome type 1
controls
response to  
C. albicans




IL-1A ↑ 0.001 ↑ 0.001
IL-1B ↑ 0.001 ↑ <0.001
il-2 → ns (0.115) ↑ 0.001
IL-3 Nd – Nd –
IL-4 ↑ <0.001 ↑ <0.001
IL-5 Nd – Nd –
IL-6 ↑ 0.014 ↑ 0.002
IL-7 ↑ 0.001 ↑ 0.037
IL-10 ↑ 0.008 ↑ 0.003
IL-12p40 ↑ 0.020 ↑ <0.001
IL-12p70 Nd – Nd –
IL-15 Nd – Nd –
il-17a → ns (0.115) ↑ <0.001
IL-18 ↑ <0.001 ↑ <0.001
il-22a → ns (0.240) ↑ 0.002
il-23 → ns (0.342) ↑ 0.035
growth factors
BDNF → Ns (0.463) → Ns (0.203)
CSF2 ↑ 0.007 ↑ 0.002
VEGFA ↑ 0.001 ↑ <0.001
chemokines
CCL2 ↑ 0.002 ↑ <0.001
CCL3 ↑ 0.001 ↑ <0.001
CCL4 ↑ <0.001 ↑ <0.001
CCL5 → Ns (0.514) → Ns (0.072)
CCL11 ↓ 0.014 ↓ 0.004
CXCL8 ↑ <0.001 ↑ <0.001
immunomodulatory cytokines
INFg ↑ 0.003 ↑ 0.014
LTA ↑ <0.001 ↑ <0.001
TNF ↑ 0.002 ↑ <0.001
adhesion molecules
ICAM1 → Ns (0.582) → Ns (0.377)
VCAM1 → Ns (0.401) → Ns (0.546)
Matrix metalloproteases
MMP3 → Ns (0.740) → Ns (0.247)
MMP9 ↑ 0.003 ↑ 0.004
(Continued )
Table 2 | Continued
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required to map a GO term ≥1, (ii) percentage of a term covered 
by proteins reliably detected by the MAPs ≥4%, and (iii) GO 
term fusion and GO term grouping was applied based on a kappa 
score of 0.4 (similarity measure between the GO terms). For each 
group of terms, the GO term accommodating the largest number 
of proteins was selected as its leading term. All other settings 
were used as per default.
resUlTs
In the TrueCulture assay, a total of 46 single mediators were ana-
lyzed in supernatants after the activation period of 48 h. Table 2 
gives an overview of all mediators analyzed, the response to 
C. albicans stimuli in patients and healthy controls, and P values 
for paired analyses within each group.
Most chemokines, interleukins, and 
immune regulatory cytokines increase  
in response to C. albicans in both 
Patients and healthy controls
Both APS-1 patients and healthy controls had a significant 
increase in levels of several mediators in response to C. albicans. 
A significant up-regulation in APS-1 and controls was found 
in the analyzed γ-chemokines CCL2, CCL3, and CCL4, the 
α-chemokine CXCL8, and the interleukins IL-1β, IL-4, IL-6, IL-7, 
IL-10, IL-12p40, and IL-18 (Table 2). Similarly, IL-1RN, the three 
immune regulatory cytokines LTA, TNF, and IFNγ and the growth 
factors CSF2 and VEGF were found to be significantly increased 
in both groups. Notably, when comparing the responses in the 
two groups, significant differences were found for 16 mediators 
(Table S1 in Supplementary Material; Figure 1). CCL11 was the 
only mediator analyzed, which significantly decreased in response 
to C. albicans in both groups. Finally, a total of 11 mediators 
analyzed remained unchanged in both groups after stimulation 
of whole blood by C. albicans (Table 2).
aPs-1 Patients have an altered Th17 
cytokine response to C. albicans 
compared to healthy controls
A subset of related mediators failed to increase in response to 
C. albicans in APS-1 patients compared to healthy controls. 
Interestingly, patients fail to increase the essential interleukins 
FigUre 1 | Mediators with significant different response in Autoimmune polyendocrine syndrome type 1 (APS-1) and controls. The figure shows selected mediators 
from the TrueCulture assay and significant differences were found comparing APS-1 and controls (C). The lines indicate the mean with standard deviation. 
Concentrations are given at the y-axis. LLOQ, lower limit of quantitation. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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IL-17A, IL-22, and IL-23 (Table 2). IL-22 was not included in 
the TrueCulture assay and, therefore, analyzed with standard 
ELISA on the TrueCulture supernatants, and IL-17A and 
IL-23 were analyzed in both assays with comparable results. 
In controls, the strength of IL-22 correlated with IL-17A (cor-
relation 0.869, P =  0.001) and IL-23 correlated with IL-17F 
(correlation 0.612, P =  0.026). These correlations could not 
be observed in patients. No APS-1 patients or controls had 
auto-antibodies against IL-23 assayed by sandwich ELISA. 
The other mediators revealing a different response in patients 
were β2-microglobulin (B2M), C3, and FGA, whereas GC 
and SERPINA1 remained unchanged in healthy controls and 
decreased significantly in APS-1 patients. All mediators with a 
significant different response comparing patients and controls 
are highlighted in Table 2.
Unsupervised hierarchical clustering 
based on changes in immune Mediators 
and Functional annotation of the Protein 
Profile characterizing the altered immune 
response in aPs-1 Patients
We used the relative values of the measured levels of all media-
tors analyzed in the TrueCulture assay in an unsupervised 
hierarchical clustering analysis (Figure  2). Patients and con-
trols were divided into two main clusters/subsets, and most 
patients were included in the left cluster (7 of 11) and most 
controls in the right cluster (9 of 13). However, no significant 
difference was found when comparing expected and observed 
frequencies using the Chi-square test (P = 0.107). Figure S1 in 
Supplementary Material shows a protein:gene ontology-(GO) 
term network, which identified four clusters of biological pro-
cesses, each with its leading term, that most efficiently intercon-
nect the nine proteins showing significantly different responses 
to C. albicans among patients and controls. Any regulatory 
relationships between the proteins, as per CluePedia v10.0, are 
displayed as well.
Monocytes from aPs-1 Patients have  
an impaired il-23p19 response When 
stimulated with curdlan
We found comparable numbers of monocytes in unstimulated 
PBMCs from patients and controls (Table 3), and no significant 
difference in frequencies of IL-23p19+ cells was found comparing 
unstimulated cultures. Although not significant, patients seem to 
have a greater variability in both numbers of monocytes when 
gating on FSC/SSC and CD14+ monocytes (Table 3; Figure S2 
in Supplementary Material). However, when comparing 
FigUre 2 | Hierarchical cluster analyses of mediator alteration in control and patients. Unsupervised hierarchical cluster analyses and distance matrix analyses for 
11 patients (red P1–P11) and 13 controls (green C1–C13) were performed. Concentrations of mediators were measured before and after intervention as previously 
described. The alterations were standardized after ratio after/before intervention and log(2) transformed before unsupervised hierarchical clustering with Squared 
Euclidean distance measure with weighted average linkage was performed, resulting in a heat map for visualization and interpretation. The mediator alteration 
profiles identified to main patients/control clusters and two main cytokine clusters.
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unstimulated and stimulated monocytes, the levels of IL-23p19 
were significantly increasing in controls, whereas this was not 
found in APS-1 (Figures  3A,B; Figure S2 in Supplementary 
Material). Moreover, healthy controls had a significant greater 
increase in total IL-23p19+ monocytes upon stimulation with 
curdlan (Figure 3C).
DiscUssiOn
Chronic mucocutaneous candidiasis as a major clinical disease 
manifestation in APS-1 suggests immune defects in mechanisms 
crucial in fungal defense. The aims of the present study were to 
characterize APS-1 patients’ immune activation in response to 
Table 3 | Monocyte counts in autoimmune polyendocrine syndrome type 1 
(APS-1) and controls.
cells aPs-1 controls P value
Monocytes [forward  
scatter (FSC)/side  
scatter (SCC)]
8.810 (1.98–16.6) 11.70 (8.32–16.00) Ns (0.0978)
CD14+ monocytes 64.9 (29.0–86.90) 79.45 (67.10–87.80) Ns (0.3355)
Interleukin (IL)-23p19+ 
monocytes – 0
0.33 (0.00–1.69) 1.00 (0.078–1.73) Ns (0.4796)
IL-23p19+ monocytes 
– curdlan
0.75 (0.00–2.32) 1.655 (0.28–3.33) Ns (0.0831)
The table gives a comparison of percent monocytes in APS-1 and controls both when 
gated on FSC/SSC and the number of CD14+ monocytes in the current monocyte 
gate. Numbers are given as median (and range). The Mann–Whitney U test was used 
for the statistical comparison.
0, baseline/unstimulated. Ns, not significant.
FigUre 3 | Interleukin (IL)-23p19 responses found in monocytes in autoimmune polyendocrine syndrome type 1 (APS-1) patients and controls. The figure gives  
an overview of the IL-23p19 response found in monocytes in patients versus controls. (a) APS-1 patients; no significant increase in IL-23p19 was detected in 
monocytes. Numbers at the Y-axis gives the percentages of IL-23p19+ monocytes after stimulation with curdlan. (b) Controls; a significant increase in IL-23p19  
was detected in monocytes. The numbers at the Y-axis give the percentages of IL-23p19+ monocytes after stimulation with curdlan. (c) Comparing the increase  
in IL-23p19+ monocytes found in APS-1 and controls at baseline and after curdlan stimulation. NS, not significant.
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C. albicans and our findings clearly state that APS-1 patients 
have an altered immune activation compared to healthy controls. 
IL-23p19, which is required for the formation of Th17 cells, was 
found dysregulated both in whole blood and monocytes upon 
stimulation with C. albicans indicating its contribution to CMC 
in patients.
The overall differences detected in the immune mediators in 
APS-1 patients have relatively broad implications on the qual-
ity of the immune response against C. albicans (Figure S1 in 
Supplementary Material). Importantly, with regard to immune 
responses against Candida, biological processes involving posi-
tive regulation of IL-17- and IL-23 production, as well as posi-
tive regulation of lymphocyte mediated immunity, were clearly 
impaired in patients. The significance of the other enriched 
biological processes impaired in patients, positive regulation of 
T-cell-mediated cytotoxicity, and immunoglobulin-mediated 
immune responses, respectively, is less obvious. However, a 
severely impaired general CD8+ T-cell homeostasis has been 
previously reported in APS-1 patients (26). The importance of 
humoral immunity against Candida is suggested to be relatively 
modest compared to cellular defense mechanisms (27). Still, the 
most important mediator in the biological process involving 
immunoglobulin mediated immune responses was the com-
plement factor C3, which APS-1 patients failed to up-regulate 
in response to C. albicans. C3 plays several important roles 
during the early innate responses against Candida, through 
opsonization and subsequently recognition and phagocytosis 
by neutrophils and monocytes (28). Moreover, comparing 
the increase in immune mediators in response to C. albicans, 
significant differences between patients and controls were 
found for several mediators (IL-1β, IL-10, IL-12p40, IL-18, 
and IL-23) involved in the crosstalk between innate immune 
cells and subsets of T cells. This indicates that several cellular 
mechanisms may be involved in altering the immune response 
in patients. NOD-like receptors are cytosolic proteins that 
are implicated in sensing fungi and, once activated, produce 
IL-1β and IL-18 through the formation of inflammasomes (29), 
both of which were less up-regulated in patients compared to 
controls in response to Candida stimulation. IL-1β is crucial 
for the differentiation of Th17  cells and for the activation 
and recruitment of neutrophil granulocytes, while IL-18 is 
important for the induction of IFNγ producing T helper 1 
(Th1) cells. IL-10 is produced by almost all immune cells and 
its major role is to limit the extent of immune activation and 
retain homeostasis (30). IL-12 is a pro-inflammatory molecule 
primarily produced by professional antigen-presenting cells 
(31) and it activates natural killer cells and induces the dif-
ferentiation of naïve CD4+ T lymphocytes to become Th1 cells 
(31). Notably, the IL-12p40 chain of IL-12 can also form a 
dimer with p19 giving rise to IL-23 (32), which is required for 
Th17 differentiation, function and maintenance. Patients failed 
to increase IL-17A, IL-22, and IL-23, which are found critical 
for optimal host defense against cutaneous candidiasis (18) 
and fungal infections (19, 20). Previous studies have reported 
conflicting results about IL-17 production in APS-1 (20, 33), 
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but the finding of reduced IL-22 producing cells in APS-1 
seems more consistent (20, 33, 34). Finally, we also confirm 
a dysregulation of IL-7, which is previously described in a 
Finnish APS-1 cohort (26). Although a more comprehensive 
study of the system biology would generate an even better 
overview of the immune activation and biological pathways 
involved in the response to Candida in APS-1, our findings 
indicate an altered immune activation in APS-1 patients, which 
includes several immune mediators that play important roles 
in immune homeostasis and particularly in the host defense 
against fungi (Figure S1 in Supplementary Material).
Interleukin-23 and Th17 cytokines have been impli-
cated in the pathogenesis of many autoimmune diseases 
(35–37), and we therefore found the total lack of IL-23 in 
APS-1 patients particularly interesting. IL-23 is secreted by 
activated monocytes and dendritic cells (38) and induces the 
differentiation of naïve T cells into Th17 cells and can promote 
the further expansion and maintenance of Th17 cells, and the 
production of Th17 cytokines via IL-23 receptor and STAT3 (38). 
In the literature, there is already conflicting information about 
IL-23 signaling in APS-1. Ryan and collaborators described 
monocyte-derived DCs from APS-1 patients to over-produce 
IL-2, INFγ, TNF-α, and IL-13 and demonstrated both impair-
ment in maturation and hyper activation in response to 
C. albicans (39). However, the IL-23 response was comparable to 
controls (39). Another study assessed Th17 responses of PBMCs 
to Candida and non-Candida species stimuli finding that PBMCs 
from APS-1 patients had a normal or increased IL-17 production 
and Th17 cell proliferation, although only in the absence of their 
own plasma, which had an inhibitory effect on both IL-17 produc-
tion and Th17 cell proliferation (34). This study reported normal 
IL-6 and IL-23 responses in APS-1 patients. Furthermore, expres-
sion levels of all pattern recognition receptors (PRRs) involved 
in anti-candida responses, levels of plasmacytoid and myeloid 
DCs, and monocyte toll-like receptor (TLR)-2/TLR-6 expression 
are described similar in APS-1 and controls (40). Finally, we 
have previously reported reduced numbers of CCR6+CXCR3+  
T helper cells, CD16+ monocytes, and Tregs in patients with 
APS-1 (41). These previous studies have investigated IL-23 from 
DCs and PBMCs in APS-1 (34, 39, 40), but less information 
about monocytes exists. We report comparable numbers of 
monocytes in both patients and controls and similar levels of 
IL-23p19 in unstimulated monocytes. Interestingly, monocytes 
from patients fail to increase IL-23p19 production both when 
comparing the steady-state levels and stimulated levels within 
each group and when comparing the total increase between the 
groups. The reason for the discrepancy in IL-23 production in 
the studies mention above and our current findings could be due 
to differences in cell types studied (PBMCs, DCs, monocytes, 
and whole blood), or that PRRs activate differently to particular 
Candida strains. These important aspects need to be further 
investigated.
Furthermore, there are conflicting information about 
the clinical relevance of monocyte-specific IL-23 signaling 
and CMC. Patients with autosomal recessive IL-12RB1 or 
IL-12p40 deficiency suffer from CMC and, therefore, indicate 
that impairment of IL-23 signaling can be the molecular 
pathogenesis of CMC (42, 43). On the other hand, CMC is 
not well described in patients with GATA2 deficiency, which 
severely impairs monocytes (44). Our findings suggest a 
monocyte-specific IL-23 deficiency in APS-1 patients, which 
resonates well with a previously published study reporting an 
extrathymic role of AIRE in monocytes (45). Specifically, that 
study described how AIRE interacts with CARD9, SYK, and 
Dectin-1 in healthy monocytes and thus plays a major role 
in activation of the Dectin-1 pathway by stimulation with 
curdlan. Consequently, PBMCs from AIRE-deficient APS-1 
patients produced significantly less TNF in response to cur-
dlan stimulation compared to healthy controls. Noteworthy, 
the expression and biological role of the AIRE protein in 
peripheral blood cells are controversial (46, 47), and the inter-
pretation of our data in this context should be approached with 
caution until the expression of AIRE in monocytes has been 
further verified. Based on the above, a general impairment in 
immune activation and an altered monocyte response prob-
ably contribute to CMC found in APS-1 and is likely to involve 
the Dectin-1 pathway.
Auto-antibodies play a key role in CMC in APS-1, and 
auto-antibodies against IL-6, IL-17A, IL-17F, IL-22, and 
IFNω are previously described (19, 20, 48). We searched for 
auto-antibodies against IL-23 in all patients without any posi-
tive findings, confirming a previous report (48). All patients 
included in our study present auto-antibodies against INFω, 
and about 60% have auto-antibodies against IL-22. To spe-
culate, these auto-antibodies may influence the difference 
in immune response found in whole blood by interacting in 
autocrine and paracrine signaling loops and thereby disturb 
cellular responses. These speculations are supported by the 
finding that APS-1 patients failed to up-regulate the interferon 
regulated serum inflammation marker B2M after C. albicans 
stimulation. The inhibition of interferon regulated genes by 
APS-1 patient auto-antibodies is well established (49), and the 
importance of type I interferons in immunity against Candida 
was recently demonstrated (50).
Our study has some limitations. First, the rarity of APS-1 makes 
biological samples limited. We therefore had to strictly prioritize 
our samples and chose to focus on stimulation assays in the search 
of differences in the protein expression using flow cytometry, rather 
than for example detecting RNA transcripts using quantitative 
polymerase chain reactions. Our cell assays were also more robust 
compared to pilot experiments of culturing PBMCs or whole 
blood with C. albicans, and analyzing supernatants for signaling 
molecules using ELISA. Second, in our cell assay, few monocytes 
produced IL-23p19 when stimulated with curdlan and some cells 
were border line positive for IL-23p19 after stimulation. However, 
we carefully optimized our assay regarding incubation time, 
concentration of Dectin, and Brefeldin A stimulation. Moreover, 
samples from two patients and two controls were always stimu-
lated and analyzed together, we used a consistent gating strategy 
when analyzing data, and our findings regarding IL-23 were 
comparable in both the cell assay and the TrueCul ture system. 
In general, whole blood assays probably mirror the in vivo condi-
tions of inflammation more precisely than PBMC assays regard-
ing interplay between subsets of immune cells and mediators. 
9
Bruserud et al. Altered Immune Activation in APS-1
Frontiers in Immunology | www.frontiersin.org September 2017 | Volume 8 | Article 1074
We found significantly altered IL-23p19/IL-23 signaling in both 
our assays making the findings reliable.
In summary, in order to gain further insights into the molecu-
lar mechanisms of CMC in APS-1, we used different approaches 
to investigate the immune activation in APS-1 in response to C. 
albicans. Our findings indicate that patients have a significant 
altered immune activation with broad implications on the qual-
ity of the immune response to C. albicans and that monocytes 
contribute to a dysregulation of the IL-23/Th17 axis, which is 
crucial for proper immunity to fungal infections.
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FigUre s1 | Functional annotation of the protein profile characterizing the 
altered immune response to C. albicans in APS-1 patients versus healthy 
individuals. This protein:gene-ontology-(GO) term network identified four clusters 
of biological processes, each with its leading term, that most efficiently 
interconnect the nine proteins here relevant. Any regulatory relationships between 
the proteins, as per CluePedia v10.0 are displayed as well.
FigUre s2 | Gating strategy for flow cytometric analyses.
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ABSTRACT
Background: Autoimmune polyendocrine syndrome type-1 (APS-1) is a rare, childhood onset
disease caused by mutations in the Autoimmune Regulator gene. The phenotypic expression
is highly variable and includes disease manifestations in the oral cavity, including mucocuta-
neous candidiasis. Increasing evidence suggests a potential role of the skin, oral and gut
microbiotas in the pathogenesis of autoimmunity. To date, no information exists regarding
the oral microbiota in APS-1.
Objective: To assess the bacterial microbiota of whole saliva in APS-1 patients by using high
throughput sequencing.
Design: Whole unstimulated saliva was collected from 10 APS-1 patients and 17 healthy
controls and examined by high throughput sequencing of the hypervariable region V1-V2 of
16S rRNA using the 454 GS Junior system. Metastats (http://cbcb.umd.edu/software/meta
stats) was used to analyse the pyrosequencing reads.
Results: A reduction in the total number of bacterial genera and species was detected in APS-
1 compared to healthy controls. The proportion of the major phyla Firmicutes was higher
(60% vs 41%, p = 0.002) and Bacteroidetes lower (15% vs 28%, p = 0.007) in APS-1 compared
to healthy controls. On the genus level, Streptococcus and Gemella were prevalent in APS-1.
Conclusion: Our findings indicate a significantly altered oral microbiota in APS-1.
ARTICLE HISTORY
Received 24 October 2017






Autoimmune polyendocrine syndrome type-1
(APS-1) or autoimmune polyendocrinopathy-candi-
diasis-ectodermal dystrophy (OMIM 240300) is a
rare, monogenic, childhood onset disorder which
is clinically defined by the presence of two of the
three major disease components: primary adrenal
insufficiency, hypoparathyroidism, and chronic
mucocutaneous candidiasis (CMC) [1]. However,
the clinical picture is highly variable and includes
many minor disease components [2]. The
Autoimmune Regulator (AIRE) gene is the disease-
causing gene [3,4]. AIRE acts as a transcriptional
regulator and is almost exclusively expressed in the
thymus [5] where it orchestrates the process of
negative selection of self-reactive T cells and con-
tributes to the development of regulatory T cells
(Tregs) [6,7]. All patients present autoantibodies
against autoantigens expressed in the affected tissue
[8] and/or against immune mediators such as inter-
feron-omega (ω) and interleukin (IL)-22 [9,10].
Interestingly, circulating autoantibodies and AIRE-
mutations can be found before development of
clinical APS-1 [11,12] making the role of
environmental triggers particularly relevant in the
pathogenesis and phenotypic expression.
Increasing evidence indicates that the environment
shapes the human immune system and accounts for its
heterogeneity among individuals [13]. The oral, gut,
and skin microbiotas could play a key role in the patho-
genesis of systemic and organ-specific autoimmune
diseases [14]. Most APS-1 patients develop disease
components affecting the oral cavity; enamel hypoplasia
and CMC are both commonmanifestations [9,15]. Also
a Sjögren’s-like syndrome without extractable nuclear
antigen autoantibodies has recently been described
[15,16]. These oral manifestations probably interfere
with the homeostasis of the oral microbiota.
Furthermore, autoimmunity against defensins and
other antimicrobial substances as observed in APS-1
could change the microbiota [17]. Reduced salivary
flow rate changes the oral microbiota [18] and in a
study of patients with severe Sjögren’s syndrome
Streptococcus salivarius, Neisseria pharyngis,
Veillonella species, and Micrococcus mucilaginosus
were reduced and the number of Staphylococcus aureus
and Candida species were increased compared to
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healthy controls [19]. Another recent study of primary
Sjögren’s syndrome patients with normal salivary flow
rate found that the number of bacterial genera and
species was lower in patients, and concluded that saliva
dysbiosis is a key characteristic of primary Sjögren’s
syndrome [20]. Moreover, changes in the oral micro-
biota are found to be associated with several other
diseases including squamous cell carcinoma, athero-
sclerosis, bacteraemia, and rheumatoid arthritis [21].
In APS-1, no information exists regarding the oral
microbiota and only a few studies of the gut micro-
biota have been reported [17,22,23]. In this study, we
characterized the bacterial profile in whole unstimu-
lated saliva of patients by high throughput sequen-
cing, a technique which recovers both cultivated and
not-yet-cultivated bacteria, thus giving an in-depth
overview of bacteria present.
Materials and methods
Patients and clinical data
A total of 10 APS-1 patients from 6 different families
were included. All patients fulfilled the diagnostic cri-
teria of APS-1. They were previously described in the
Norwegian cohort [9,24,25] and included in our
National Registry of Autoimmune Diseases. Three
patients were excluded after an initial quality control.
A detailed characterization of the seven remaining
patients (five females and two males) is given in
Table 1. The mean age was 32.3 years (range 10–64).
All participants had their disease onset before the age of
8 years. Three patients presented the three major dis-
ease components and the mean number of disease
components was five (range 4–7). Enamel hypoplasia
was found in all patients. CMC was previously diag-
nosed in five patients and three had oral candidiasis at
the time of sampling (Table 1). Disease-causing AIRE-
mutations and autoantibodies against interferon-ω
were present in all. All participants gave informed and
written consent and the study was approved by The
Regional Committee for Medical and Health Research
Ethics for Western Norway.
Saliva sampling and sample processing
Whole unstimulated saliva was collected from patients
(n = 10) and healthy controls (n = 17) with the same age
and sex distributions as patients. Saliva samples were
collected between 9 a.m. and 11 a.m., and participants
were asked not to brush their teeth, eat, or drink for at
least 2 h before sampling. No participants were regular
smokers or had received antibiotics within the lastmonth
before sampling. Saliva pH was measured using a strip
Table 1. Characteristics of the APS-1 patients. The age at diagnosis for each disease component is written in parentheses. The
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21OH, 21-hydroxylase; 17OH, 17-α-hydroxylase; AADC, aromatic L-amino acid decarboxylase; Al, alopecia; AT, autoimmune thyroiditis; B12, vitamin-B12
deficiency; CMC, candidiasis; E, enamel hypoplasia; G, hypogonadism; GAD65, glutamic acid decarboxylase 65-kDA isoform; HP, hypoparathyroidism;
IL17, interleukin-17; IL22, interleukin-22; INF-ω, interferon-omega; M, malabsorption; MAGEB2, melanoma antigen B2; NALP5, NACHT leucine-rich-
repeat protein 5; PAI, primary adrenocortical insufficiency; PCA, parietal cell autoantibodies; PDILT, protein disulphide isomerase-like testis expressed;
SCC, side-chain-cleavage enzyme; SOX10, sex determining region Y-box 10; TGM4, transglutaminase 4; TPH1, tryptophan hydroxylase 1; TH, tyrosine
hydroxylase; V, vitiligo; YoB, year of birth, nd; not done.
*Standard methods were used for culturing Candida albicans.
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test (mColorpHast™ pH Test Strips, MilliporeSigma) and
standard methods were used for culturing Candida
albicans. Unstimulated saliva flow rate (ml/min) was
measured based on a collection period of 15 min
(Table 1). Samples were immediately stored at −80°C
until analysis.
Sample processing was done as previously described
[20,26]. In summary, DNA was extracted from a
250 µl sample volume using the MasterPure™ DNA
Purification kit (Epicentre, Illumina Company,
Madison, WI) and was dissolved in 45 µl 1 × TE
buffer. The 16S rRNA hypervariable region V1-V2
was amplified in three parallel PCRs and sequenced
on a 454 GS Junior System (Roche, Branford, CT).
Primer sequences and amplifications reactions are
given previously [20]. DNA quality and concentrations
were assessed with Bioanalyzer 2100 (Agilent, Santa
Clara, CA) and Nanodrop 3300 Flurospectrometer
(Thermo Scientific, Wilmington, DE), all within the
range to perform high throughput sequencing.
Bioinformatics analysis of sequence reads
Bioinformatics analysis of sequence reads was executed
as described previously [20]. In brief, raw sequence
reads were subjected to a species-level, reference-based
taxonomy assignment especially designed for studying
the human oral microbial community [20]. The set of
16S rRNA reference sequences previously published by
Al-Hebshi et al. [27] and the NCBI 16S rRNA reference
sequence set (ftp://ftp.ncbi.nlm.nih.gov/blast/db/
16SMicrobial.tar.gz) were combined giving reference
sequences representing a total of 1,151 oral and 12,013
non-oral species that were BLASTN-searched for each
of the sequence reads. Unassigned reads were then
screened for high-quality non-chimeras and subjected
to de novo species-level operational taxonomy unit call-
ing for potential novel species. The quantitative insights
into microbial ecology pipeline software package ver-
sion 1.9.1 [28] was used for down-stream analyses,
including alpha and beta diversities. A statistical
method introduced in Metastats (http://cbcb.umd.edu/
software/metastats) was used to reveal significant dif-
ferences between the microbiota of control saliva and
APS-1 saliva. This method employs a false discovery
rate to improve specificity in high complexity environ-
ments, and handles sparsely sampled features using
Fisher’s exact test [29]. p-values ≤ 0.05 were considered




An overview of the sequence read counts in each
analysis step is given in Supplemental Table 1.
Composition of the salivary microbiota of APS-1
patients
Five different phyla were detected in APS-1 patients
with DNA sequences predominately assigned to the
phyla Firmicutes (60%), Bacteroidetes (15%),
Proteobacteria (10%), Fusobacteria (8%), and
Actinobacteria (6%). Table 2 gives an overview of
the significantly different abundances of taxa from
control saliva and APS-1 saliva by phyla, genera and
species, respectively. In Figure 1, a comparison of the
bacterial content of saliva in APS-1 and controls
based on the sequencing of the hypervariable 16S
rDNA region V1-V2 is presented. Saliva from APS-
1 displayed a significantly increased relative abun-
dance of Firmicutes (p = 0.002) and a lower fre-
quency of Bacteroidetes (p = 0.007) compared with
controls (Figure 2).
A total of 64 bacterial genera were detected in
APS-1 and 90 in healthy controls. Figure 3 gives
the relative abundances of the 18 major genera
found in APS-1 samples and controls. Moreover,
a total of 18 genera showed significant differences
in abundances (Table 2). Metastats analyses
showed that the genera Streptococcus and
Gemella were significantly higher in patients than
controls (p = 0.0001 and 0.036, respectively;
Figure 4) whereas Prevotella and Veillonella were
significantly higher in controls (p = 0.001 and
<0.001, respectively; Figure 4). Among the genera
with significant difference in abundance, eight
genera were absent from whole saliva of APS-1
patients (Table 2).
In APS-1 patients, the sequencing data revealed
the most abundant species to be Streptococcus sp.
str. C300, Streptococcus multispecies spp.24_2,
Streptococcus mitis, Streptococcus infantis, and
Haemophilus parainfluenzae. Among these, only
Streptococcus sp. str. C300 and Streptococcus multi-
species spp.24_2 were increased compared to controls
(p = 0.001, 0.032, respectively). The other species
found more abundant in APS-1 patients were
Fusobacterium nucleatum subsp. animalis, Gemella
haemolysans, Ruminococcaceae [G-3] sp. Oral taxon
366, and Capnocytophaga ochracea (p = 0.046, 0.047,
<0.001, 0.002, respectively). The Veillonella parvula
group and Prevotella melaninogenica were most
abundant in controls. Table 2 shows all species with
significant differences in abundance compared to
control saliva and APS-1 saliva as estimated by
Metastats.
Species richness and diversity
Samples from healthy controls had a higher species
richness and diversity than APS-1 samples. Figure 5
(a) illustrates that the average species richness is
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higher in healthy subjects based on the observed
species rarefaction curves Figure 5(b,c) gives the
estimated species richness evaluated on the Chao1
matrix and the rarefaction curves based on the
Shannon index, respectively showing an overall dif-
ference in alpha diversity, although the latter shows
no difference between health and APS-1. However,
the Shannon index measures both richness and
abundance, hence the evenness of the community.
Figure 5(c) therefore indicates that there is no sig-
nificant difference between APS-1 and controls in
terms of species evenness. Finally, Figure 5(d) gives
Table 2. Differences in abundances of taxa in APS-1 and control saliva. Significant (p ≤ 0.05) differences in relative abundance of
taxa from control saliva and APS-1 saliva as estimated by Metastats http://cbcb.umd.edu/software/metastats. Differences
significant after Bonferonni Correction for multiple testing are marked with *.
Taxon APS-1 saliva (n = 7) Control saliva (n = 17) Metastat p-value
Phyla
Firmicutes 0.65118 ± 0.02551 0.41118 ± 0.02572 0.002
Bacteroidetes 0.11271 ± 0.03162 0.26009 ± 0.03845 0.007
Genera
Streptococcus 0.53448 ± 0.08523 0.18016 ± 0.01963 0.0001*
Gemella 0.01467 ± 0.00023 0.00253 ± 0.00062 0.036
Prevotella 0.05995 ± 0.01021 0.17357 ± 0.02970 0.001
Veillonella 0.04049 ± 0.00925 0.16254 ± 0.02760 0.0001*
Neissera 0.02065 ± 0.00965 0.05508 ± 0.01269 0.029
Actinomyces 0.00148 ± 0.00055 0.00673 ± 0.00159 0.002
Megashaera 0.00000 0.00631 ± 0.00287 0.027
Lachnospiraceae_ [G-3] 0.00059 ± 0.00033 0.00417 ± 0.00097 0.001
Lachnoanaerobaculum 0.00024 ± 0.00019 0.00123 ± 0.00033 0.008
Eubacterium_[XIVa][G-1] 0.00025 ± 0.00018 0.00109 ± 0.00031 0.019
Ruminococcaceae_[G-3] 0.00002 ± 0.00776 0.00119 ± 0.00448 0.016
Bacteroides 0.00000 0.00049 ± 0.00019 0.012
Veillonella 0.00000 0.00053 ± 0.00025 0.031
Bacteroidetes_[G-3] 0.00000 0.00032 ± 0.00010 0.002
Peptostreptococcaceae_[XI][G-4] 0.00000 0.00023 ± 0.00011 0.034
Mitsuokella 0.00000 0.00033 ± 0.00016 0.038
Desulfovibrio 0.00000 0.00405 ± 0.00040 0.018
Catonella 0.00000 0.00015 ± 0.00013 0.048
Species
Streptococcus sp._str._C300 0.12958 ± 0.03003 0.03065 ± 0.00618 0.001
Streptococcus multispecies_spp24_2 0.11555 ± 0.05022 0.00877 ± 0.00349 0.031
Fusobacterium nucleatum_ss_animalis 0.02401 ± 0.01178 0.00083 ± 0.00038 0.046
Gemella haemolysans 0.01308 ± 0.00599 0.00132 ± 0.00047 0.047
Capnocytophaga ochracea 0.00112 ± 0.00035 0.00004 ± 0.00002 0.023
Veillonella parvula_group 0.03273 ± 0.00653 0.10745 ± 0.01904 0.0003*
Prevotella melaninogenica 0.02205 ± 0.00876 0.09752 ± 0.01762 0.0002*
Veillonella atypica 0.00776 ± 0.00389 0.05509 ± 0.01369 0.001
Neisseria flavescens/subflava 0.01723 ± 0.00873 0.04995 ± 0.01204 0.023
Porphyromonas gingivalis 0.00000 0.02849 ± 0.01465 0.048
Prevotella pallens 0.00059 ± 0.00036 0.02308 ± 0.00617 0.0004*
Campylobacter concisus 0.00133 ± 0.00083 0.01390 ± 0.00382 0.001
Prevotella salivae 0.00054 ± 0.00024 0.00848 ± 0.00293 0.006
Prevotella veroralis_nov_95.28% 0.00000 0.00723 ± 0.00287 0.010
Solobacterium moorei 0.00251 ± 0.00121 0.00638 ± 0.00154 0.045
Megasphare micronuciformis 0.00000 0.00631 ± 0.00287 0.023
Atopobium parvulum 0.00099 ± 0.00026 0.00579 ± 0.00223 0.028
Lachnospiraceae_[G-3] sp._oral_taxon_100_nov_83.29% 0.00049 ± 0.00032 0.00342 ± 0.00082 0.001
Actinomyces sp._Oral_Taxon_180 0.00043 ± 0.00022 0.00328 ± 0.00103 0.006
Actinomyces odontolyticus 0.00047 ± 0.00015 0.00247 ± 0.00062 0.001
Prevotella multispecies_sppn1_2_nov_82.34% 0.00027 ± 0.00019 0.00158 ± 0.00579 0.026
Lachnoanaerobaculum orale 0.00024 ± 0.00019 0.00123 ± 0.00332 0.008
Eubacterium_[XIVa][G-1] saburreum 0.00025 ± 0.00018 0.00109 ± 0.00313 0.016
Tannerella forsythia_nov_96.52% 0.00000 0.00095 ± 0.00311 0.002
Aggregatibacter aphrophilus 0.00000 0.00080 ± 0.00035 0.018
Porphyromonas gingivalis_nov_96.46% 0.00000 0.00079 ± 0.00037 0.026
Leptotrichia sp._oral_taxon_219_nov_83.33% 0.00021 ± 0.00019 0.00077 ± 0.00020 0.039
Fretibacterium fastidiosum 0.00000 0.00074 ± 0.00033 0.019
Ruminococcaceae_[G-3] sp._oral_taxon_366_nov_78.83% 0.00002 ± 0.00002 0.00054 ± 0.00015 0.001
Veillonella sp._oral_taxon_780_nov_82.14% 0.00000 0.00053 ± 0.00025 0.029
Mogibacterium neglectum 0.00010 ± 0.00008 0.00051 ± 0.00190 0.044
Haemophilus parainfluenzae_nov_96.89% 0.00000 0.00043 ± 0.00026 0.018
Desulfovibrio sp._oral_taxon_040 0.00000 0.00040 ± 0.00040 0.018
Mitsuokella sp._Oral_Taxon_H31_nov_78.38% 0.00000 0.00033 ± 0.00016 0.035
Streptococcus constellatus_nov_80.22% 0.00000 0.00032 ± 0.00013 0.008
Porphyromonas gingivalis_nov_91.05% 0.00004 ± 0.00004 0.00032 ± 0.00011 0.019
Bacteroidetes_[G-3] sp._oral_taxon_280_nov_92.66% 0.00000 0.00031 ± 0.00010 0.015
Alloprevotella rava_nov_86.47% 0.00000 0.00029 ± 0.00009 0.002
Fretibacterium sp._oral_taxon_359 0.00000 0.00025 ± 0.00016 0.029
Prevotella sp._oral_taxon_515_nov_80.56% 0.00000 0.00024 ± 0.00013 0.018
Prevotella sp._oral_taxon_515_nov_78.25% 0.00000 0.00023 ± 0.00016 0.029
Peptostreptococcaceae_[XI][G-4] sp._oral_taxon_369 0.00000 0.00022 ± 0.00011 0.031
Catonella sp._oral_taxon_164_nov_95.73% 0.00000 0.00015 ± 0.00014 0.048
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a PCoA 3D plot of all samples with the distances
calculated using weighed normalized UniFrac
matrix, and clearly indicates that the two groups
have distinct beta diversity. Taken together, these
results show a richer diversity in controls compared
to APS-1.
Figure 1. Bacterial phyla detected in APS-1 patients (n = 7) and control saliva (n = 17). Comparison of microbiota in APS-1 and
healthy saliva determined by sequencing the hypervariable 16S rDNA region V1-V2. Relative abundance of the different phyla in
control and APS-1 samples is shown.
Figure 2. The relative abundances of the phyla Bacteroidetes and Firmicutes in saliva of healthy controls (n = 17) and APS-1
patients (n = 7) illustrated with boxplots. The lines indicate means and standard deviations.
Figure 3. Bacterial genera detected in saliva from APS-1 patients (n = 7) and controls (n = 17). Groups designated as ‘Other’
represents minor groups classified. The Y-axis represents relative abundance. An increase in the genus Streptococcus in APS-1
saliva relative to control saliva is demonstrated.
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Discussion
Increasing evidence suggests a potential role of the
skin, oral, and gut microbiotas in the pathogenesis of
autoimmunity [14]. Using high throughput sequen-
cing and a comprehensive bioinformatics approach to
analyse next generation 16S rDNA pyrosequencing
reads, we here present hitherto undescribed signifi-
cant differences in the composition of the salivary
microbiota comparing APS-1 patients and healthy
controls, indicating a possible contribution in patho-
genesis and clinical expression.
Figure 4. The relative abundances of the genera Streptococcus, Gemella, Prevotella, and Veillonella in saliva of healthy controls
(n = 17) and APS-1 patients (n = 7) illustrated with boxplots. The lines indicate means and standard deviations.
Figure 5. Comparison of microbial diversity in saliva samples of APS-1 patients (n = 7) and health samples (n = 17). Average
rarefaction curves of APS-1 and health samples reported as (a) observed species, (b) Chao1 estimator, (c) Shannon index, (d)
PCoA 3D plots of all samples with distances calculated using weighed normalized UniFrac matrix. Blue curves and dots represent
health samples; and red represents APS-1.
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The most striking differences were a higher por-
tion of Firmicutes and a reduction of Bacteroidetes
in APS-1 patients. Similar findings were recently
described in primary Sjögrens syndrome [20] and a
reduced species diversity and an altered ratio between
Firmicutes and Bacteroidetes were described in the
intestinal microbiota in several autoimmune diseases
[30–33]. However, Firmicutes represents a phylum
where most bacteria have a Gram-positive cell wall
including the oral genera Streptococcus, Lactobacillus,
Selenomonas, Clostridium, and Eubacterium. The
phylum Bacteroidetes is composed of Gram-negative
bacteria. On a genus level, Streptococcus and Gemella
were increased in APS-1. However, a reduction in the
total number of bacterial genera was seen. Overall,
these novel findings indicate a significant altered oral
microbiota in APS-1.
This is the first report on the oral microbiota in
APS-1, and only a few studies have investigated the
gut microbiota in patients [17,22,23]. A comparative
analysis of the intestinal microbiota of APS-1 patients
with gastrointestinal manifestations showed signifi-
cant enrichment of segmented filamentous bacteria
[17], which are Gram-positive commensal bacteria
with the potential to adhere to epithelial cells and
induce T helper (Th) 17 responses. Another study
reported that APS-1 patients develop early and sus-
tained responses to gut microbial antigens reminis-
cent to Crohn’s disease [23] linked to defects in
Tregs. Finally, products from commensal bacteria
have the potential to indirectly regulate thymic Aire
expression in mice [22]. Based on the above, this
indicates that the microbiota contributes in shaping
immunity in APS-1 although the molecular mechan-
isms are incompletely characterized.
Factors known to directly affect the immune sys-
tem, and consequently, the risk of autoimmunity,
such as genetics, gender, and diet may also exert
their effects by modulating microbiota profiles and
functions. Using animal models of experimental coli-
tis [34] and arthritis [35] it was shown that Gram-
negative bacteria, possibly through the TLR2/IL-10
axis, reduced inflammation [34], whereas Gram-posi-
tive bacteria contributed to a more severe disease
[35]. In a mouse model of Sjögren’s disease, depletion
of the intestinal microbiome worsened the ocular
response to desiccation, while the overall severity of
disease correlated with intestinal microbiome diver-
sity [36]. Two recent characterizations of the oral
microbiota in primary Sjögren’s syndrome demon-
strated a significant shift in the oral microbiota of
patients and reduced numbers of genera [20,37], sug-
gesting a role of the oral microbiota in the pathogen-
esis. Interestingly, these findings are comparable to
what we currently describe in APS-1.
CMC caused by C. albicans is the most common
and earliest manifestation of APS-1 [2]. The clinical
course varies from periodical to chronic and usually
affects the oral mucosa [1,2,9]. To date, neutralizing
autoantibodies against the Th17 cytokines IL-17A, IL-
17F, and IL-22 are suggested to explain the impairment
in mucosal immunity in APS-1 patients [10,38].
However, an important line of defence against oral
CMC is the oral microbiota that prevents infections
by their interplay with immune cells, nutrients, meta-
bolic products and by secreting antagonistic molecules,
which together balance local inflammatory responses
[39]. C. albicans can form biofilms with many oral
bacteria, including streptococci [40], which have syner-
gistic or antagonistic influences on C. albicans.
Noteworthy, recent work has highlighted the critical
role of metabolic products from specific gut microbiota
such as lactobacilli in priming IL-22 dependent muco-
sal immune responses by innate lymphoid cells via the
aryl hydrocarbon receptor, which is fundamental for
protection against uncontrolled local Candida expan-
sion [41]. Further, a shift in salivary microbiota has
been linked to the risk of oral cancer in selected groups
of patients [42]. We found significantly increased
abundance of streptococci in APS-1 saliva compared
to healthy controls and several streptococci were
among the most abundant species in APS-1 saliva. To
speculate, an altered microbiota may change the profile
of immune regulatory metabolic products, and thus,
contribute in altering immunity in APS-1 patients. Still
it remains unclear whether an altered microbiota
causes disease manifestations or the altered microbiota
is an effect of disease components.
The obvious drawbacks of this study are the low
number of patients included and the heterogeneity
within this group. Initially 10 patients were included
but technical issues with the sequencing made us
exclude 3 patients. We plan to include more patients
trying to correlate the different taxa to clinical man-
ifestations of APS-1 and calculate absolute microbial
abundances using a quantitative polymerase chain
reactions assay. The same approach could be used to
characterize the skin and the gut microbiotas in
APS-1.
In conclusion, the oral microbiota in APS-1
patients is altered compared to healthy controls
and seems to be a characteristic of the syndrome.
In general, the skin, oral, and intestinal microbio-
tas in APS-1 patients should be further investi-
gated to reveal their potentially contribution in
pathogenesis and phenotypic expression of the
syndrome.
Acknowledgments
The authors would like to thank the DNA Sequencing
Facility, Department of Biochemistry, University of
Cambridge for sequencing services (http://www.bioc.cam.
ac.uk/dnasequencing).
JOURNAL OF ORAL MICROBIOLOGY 7
Disclosure statement
No potential conflict of interest was reported by the
authors.
Funding
This study was supported by grants from the University of
Bergen, the Bergen Research Foundation, Stiftelsen KG
Jebsen, the Regional Health Authorities of Western
Norway (grant no 977878), The Norwegian Research
Council (grant no 213704) and the Novo Nordisk
Foundation (grant no NNF14OC0011005). IO was funded
by the European Commission (FP7-HEALTH-306029
‘TRIGGER’). RJ was funded by EU H2020 contract
HarmonicSS (contract nr: H2020-SC1-2016-RTD/731944)
and the Broegelmann Foundation. Grant from Research
Council of Norway (250030) to BEO
Notes on contributors
Øyvind Bruserud is MD and PhD-fellow at the University
of Bergen with research interests in autoimmune polyen-
docrine syndrome type 1.
Huma Siddiqui is a molecular microbiologist with experi-
ence in genomics and metagenomics. At the Department of
Oral Biology, Faculty of Dentistry, University of Oslo, she
has been researching the genomics of oral bacteria.
Mihaela Cuida Marthinussen is DMD and associate pro-
fessor in the field of clinical dentistry at the University of
Bergen. Her main research interest is use of saliva as a
diagnostic tool.
Tsute Chen is an associate research investigator at The
Forsyth Institute, Cambridge, MA, USA and an instructor
of the Department of Oral Medicine, Infection and
Immunity, Harvard School of Dental Medicine, Boston,
MA, USA. Tsute Chen’s research interests include studies
of human oral microbiome in both taxonomy and geno-
mics. Tsute Chen is one of the authors of the ‘Human Oral
Microbiome Database’ (http://www.homd.org) and has
been developing bioinformatics software tools for analysing
the NGS genomic and transcriptomic data.
Roland Jonsson is DMD, PhD and professor at the
University of Bergen and head of Broegelmann Research
Laboratory. He has a particular interest in Sjögren’s
syndrome.
Bergithe Eikeland Oftedal is an immunologist working in
the field of immunogenetics. She has a particular interest in
the development of T cells and how this shapes the
immune repertoire. She is currently a visiting scientist at
the University of Oxford.
Ingar Olsen is professor emeritus and guest researcher at
Department of Oral Biology, Faculty of Dentistry,
University of Oslo. Senior Research Investigator,
Department of Microbiology, Forsyth Institute,
Cambridge, MA. DDS from the Faculty of Dentistry,
University of Oslo in 1966. Dr Odont. In 1976. Professor
in oral microbiology 1988. Dean for research 2002-2008.
Previously, main supervisor of more than 20 PhD students.
Eystein Husebye is professor of endocrinology at the
University of Bergen with research interest in autoimmune
endocrine diseases, in particular Addison’s disease and
autoimmune polyendocrine syndrome type 1.
Bøe Wolff is a senior researcher in the field of molecular
biology and immunology at the University of Bergen. Her
main research interest is to understand background
mechanisms for autoimmune diseases.
ORCID
Bergithe Eikeland Oftedal http://orcid.org/0000-0003-
4248-7737
Anette Bøe Wolff http://orcid.org/0000-0002-8485-2248
References
[1] Perheentupa J. Autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy. J Clin Endocrinol
Metab. 2006;91:2843–2850.
[2] Husebye ES, Perheentupa J, Rautemaa R, et al. Clinical
manifestations and management of patients with auto-
immune polyendocrine syndrome type I. J Intern
Med. 2009;265:514–529.
[3] Nagamine K, Peterson P, Scott HS, et al. Positional
cloning of the APECED gene. Nat Genet.
1997;17:393–398.
[4] Consortium F-GA. An autoimmune disease,
APECED, caused by mutations in a novel gene featur-
ing two PHD-type zinc-finger domains. Nat Genet.
1997;17:399–403.
[5] Pitkänen J, Vähämurto P, Krohn K, et al. Subcellular
localization of the autoimmune regulator protein.
Characterization of nuclear targeting and transcrip-
tional activation domain. J Biol Chem.
2001;276:19597–19602.
[6] Anderson MS, Venanzi ES, Klein L, et al. Projection of
an immunological self shadow within the thymus by
the aire protein. Science. 2002;298:1395–1401.
[7] Yang S, Fujikado N, Kolodin D, et al. Immune toler-
ance. Regulatory T cells generated early in life play a
distinct role in maintaining self-tolerance. Science.
2015;348:589–594.
[8] Söderbergh A, Gustafsson J, Ekwall O, et al.
Autoantibodies linked to autoimmune polyendocrine
syndrome type I are prevalent in Down syndrome.
Acta Paediatr. 2006;95:1657–1660.
[9] Bruserud O, Oftedal BE, Landegren N, et al. A long-
itudinal follow-up of autoimmune polyendocrine syn-
drome type 1. J Clin Endocrinol Metab.
2016;101:2975–2983.
[10] Kisand K, Wolff ASB, Podkrajsek KT, et al. Chronic
mucocutaneous candidiasis in APECED or thymoma
patients correlates with autoimmunity to Th17-asso-
ciated cytokines. J Exp Med. 2010;207:299–308.
[11] Meager A, Visvalingam K, Peterson P, et al. Anti-
interferon autoantibodies in autoimmune polyendo-
crinopathy syndrome type 1. PLoS Med. 2006;3:
e289.
[12] Wolff AS, Sarkadi AK, Maródi L, et al. Anti-cytokine
autoantibodies preceding onset of autoimmune poly-
endocrine syndrome type I features in early child-
hood. J Clin Immunol. 2013;33:1341–1348.
[13] Brodin P, Jojic V, Gao T, et al. Variation in the human
immune system is largely driven by non-heritable
influences. Cell. 2015;160:37–47.
8 Ø. BRUSERUD ET AL.
[14] Shamriz O, Mizrahi H, Werbner M, et al. Microbiota
at the crossroads of autoimmunity. Autoimmun Rev.
2016;15:859–869.
[15] Ferre EM, Rose SR, Rosenzweig SD, et al. Redefined
clinical features and diagnostic criteria in autoimmune
polyendocrinopathy-candidiasis-ectodermal dystro-
phy. JCI Insight. 2016;1.
[16] Oftedal BE, Marthinussen MC, Erichsen MM, et al.
Impaired salivary gland activity in patients with auto-
immune polyendocrine syndrome type I.
Autoimmunity. 2017;50:211–222.
[17] Dobeš J, Neuwirth A, Dobešová M, et al.
Gastrointestinal autoimmunity associated with loss of
central tolerance to enteric alpha-defensins.
Gastroenterology. 2015;149:139–150.
[18] AlmståhI IA, Wikström M, Stenberg I, et al. Oral
microbiota associated with hyposalivation of different
origins. Oral Microbiol Immunol. 2003;18:1–8.
[19] MacFarlane TW. The oral ecology of patients with
severe Sjogren’s’ syndrome. Microbios. 1984;41:99–106.
[20] Siddiqui H, Chen T, Aliko A, et al. Microbiological
and bioinformatics analysis of primary Sjogren’s syn-
drome patients with normal salivation. J Oral
Microbiol. 2016;8:31119.
[21] He J, Li Y, Cao Y, et al. The oral microbiome diversity
and its relation to human diseases. Folia Microbiol
(Praha). 2015;60:69–80.
[22] Nakajima A, Negishi N, Tsurui H, et al. Commensal
bacteria regulate thymic Aire expression. PLoS One.
2014;9:e105904.
[23] Hetemäki I, Jarva H, Kluger N, et al. Anticommensal
responses are associated with regulatory T cell defect in
autoimmune polyendocrinopathy-candidiasis-ectoder-
mal dystrophy patients. J Immunol. 2016;196:2955–
2964.
[24] Wolff AS, Erichsen MM, Meager A, et al.
Autoimmune polyendocrine syndrome type 1 in
Norway: phenotypic variation, autoantibodies, and
novel mutations in the autoimmune regulator gene. J
Clin Endocrinol Metab. 2007;92:595–603.
[25] Myhre AG, Halonen M, Eskelin P, et al. Autoimmune
polyendocrine syndrome type 1 (APS I) in Norway.
Clin Endocrinol (Oxf). 2001;54:211–217.
[26] Siddiqui H, Nederbragt AJ, Lagesen K, et al. Assessing
diversity of the female urine microbiota by high
throughput sequencing of 16S rDNA amplicons.
BMC Microbiol. 2011;11:244.
[27] Al-Hebshi NN, Nasher AT, Idris AM, et al. Robust
species taxonomy assignment algorithm for 16S rRNA
NGS reads: application to oral carcinoma samples. J
Oral Microbiol. 2015;7:28934.
[28] Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME
allows analysis of high-throughput community
sequencing data. Nat Methods. 2010;7:335–336.
[29] White JR, Nagarajan N, Pop M. Statistical methods for
detecting differentially abundant features in clinical
metanogenic samples. PLoS Comput Biol. 2009;5:
e1000352.
[30] Giongo A, Gano KA, Crabb DB, et al. Toward defin-
ing the autoimmune microbiome for type 1 diabetes.
Isme J. 2011;5:82–91.
[31] Bhagava P, Moury EM. Gut microbiome and multiple
sclerosis. Curr Neurol Neurosci Rep. 2014;492.
[32] Chen J, Wright K, Davis JM, et al. An expression of
rare lineage intestinal micobes characterizes rheuma-
toid arthritis. Genome Med. 2016;8:43.
[33] Hevia A, Milani C, López P, et al. Intestinal dysbiosis
associated with systemic lupus erythematosus. MBio.
2014;30(5):e01548–14.
[34] Oppong GO, Rapsinski GJ, Tursi SA, et al. Biofilm-
associated bacterial amyloids dampen inflammation in
the gut: oral treatment with curli fibres reduces the
severity of hapten-induced colitis in mice. NPJ
Biofilms Microbiomes. 2015;1.
[35] Kohashi O, Kohashi Y, Takahashi T, et al. Reverse
effect of gram-positive bacteria vs. gram-negative bac-
teria on adjuvant-induced arthritis in germfree rats.
Microbiol Immunol. 1985;29:487–497.
[36] de Paiva CS, Jones DB, Stern ME, et al. Altered muco-
sal microbiome diversity and disease severity in
Sjogren syndrome. Sci Rep. 2016;6:23561.
[37] Li M, Zou Y, Jiang Q, et al. A preliminary study of the
oral microbiota in Chinese patients with Sjogren’s
syndrome. Arch Oral Biol. 2016;70:143–148.
[38] Puel A, Döffinger R, Natividad A, et al.
Autoantibodies against IL-17A, IL-17F, and IL-22 in
patients with chronic mucocutaneous candidiasis and
autoimmune polyendocrine syndrome type I. J Exp
Med. 2010;207:291–297.
[39] Salvatori O, Puri S, Tati S, et al. Innate immunity and
saliva in Candida albicans-mediated oral diseases. J
Dent Res. 2016;95:365–371.
[40] Harriott MM, Noverr MC. Importance of Candida-
bacterial polymicrobial biofilms in disease. Trends
Microbiol. 2011;19:557–563.
[41] Zelante T, Iannitti RG, Cunha C, et al. Tryptophan
catabolites from microbiota engage aryl hydrocarbon
receptor and balance mucosal reactivity via interleu-
kin-22. Immunity. 2013;39:372–385.
[42] Furquim CP, Soares GM, Ribeiro LL, et al. The sali-
vary microbiome and oral cancer risk: A pilot study in
fanconi anemia. J Dent Res. 2017;96(3):292–299.




unication Division, UiB  /  Print: Skipnes Kom
m
unikasjon AS
uib.no
ISBN: 978-82-308-3563-0
